001-MCS -40-106- RD-03(13.0)/Saved on:05Aug 2015
Clinical Trial Protocol
TITLE PAGE
Document Number: c08917790 -[ADDRESS_915701] No.:
EU Trial No:2016-000613-79
BI Trial No.: 1297.[ADDRESS_915702](s):BI 695501
Title:Efficacy, S afety ,and Immunogenicity of BI 695501 versus Humira®in 
Patients with Moderate to Severe Chronic Plaque Psoriasis: A 
Randomized, Double -Blind, Parallel -Arm, Multiple -Dose, Active 
Comparator T rial
Lay Title :Efficacy, S afety , and Immunogenicity of BI 695501 versus Humira®in 
Patients with M oderate to Severe Chronic Plaque P soriasis
Clinical Phase:Phase III
Trial Clinical Monitor:
Tel.: 
Coordinating 
Investigator:
[INVESTIGATOR_36113].:
Fax.: 
Status:Final Protocol
Version and Date: Version: 1.0 Date: 26Apr 2016
Page 1 of 84
Proprietary confidential information .
2016 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 2of 84
Proprietary confidential information © [ADDRESS_915703]-03(13.0)/Saved on: 05 Aug 2015CLINICAL TRIAL PROTO COL SYNOPSIS
Nam e of company: Boehringer Ingelheim 
Nam e of finished product:NA
Nam e of active ingredient:BI 695501
Protocol date:
26Apr2016Trial number:
1297.12Revision date:
Title of trial: Efficacy, S afety , and Immunogenicity of BI 695501 versus Humira®in Patients 
with Moderate to S evere Chronic Plaque Psoriasis: A Randomized, Double- Blind, 
Parallel -Arm, M ultiple -Dose, Active Comparator Trial
Coordinating
Investigator:
[INVESTIGATOR_23207](s): Multi -national, multi -center trial in approximately 50clinical sites across 
approximately 1 0 countries
Clinical phase: Phase III
Objective(s): The primary objective of this trial isto evaluate equivalence in efficacy between BI 
695501 and US -licensed Humira®at Week 16 in patients with active moderate to 
severe chronic plaque psoriasis.
The secondary objectives of this trial are to compare the safety andefficacy
profiles of BI 695501 and US -licensed Humira. 
 
Methodology: This is a randomized , double- blind, parallel -arm, multiple -dose, active com parator 
trial of BI 695501 and US -licensed Humir awith a screening period of up to 
28days, a 24 -week treatment period and a 10 -week safety follow -up period in 
patients with chronic plaque psoriasis and a primary endpoint assessment at 
Week16.
Patients will be randomized 1:1 to either BI 695501 or Humira .Each patient will 
receive 80 mg of BI 695501 or US -licensed Humir aat Baseline (Randomiz
ation) 
(Day  1, Week 0), follow ed by 40 mg of BI 695501 or Humir a 1week later
(Week 1), and then 40 mg of BI 695501 or Humir aevery other w eek. After 
Week16,only patients who achieve a 50% reduction in Psoriasis Area and 
Severity Index (PASI 50)will continue th e trial receiving their originally
randomiz ed treatment. Those patients not achieving at least PASI 50 w ill not be 
treated further with the study drugs but only followed up for safety.
No. of patients: 
Total entered:Approximately 300patients will be randomized.
Each treatm ent: Patients will be allocated to treatment in a 1:1 ratio to receive BI 695501 or 
US-licensed Humira.
Diagnosis : Moderate tosevere chronic plaque psoriasis .
Main criteria
for inclusion:This study will include m ale or female participants at least [ADDRESS_915704] 
6months duration . The patient’s chronic plaque psoriasis must have been stable for 
the last [ADDRESS_915705] hav e a PASI score ≥ 12, Static Physician’s Global 
Assessment of psoriasis (sPGA) ≥ 3, and a body surface area (BSA) involvement ≥ 
10% at Screening and at baseline. Patients must be suitable for systemic treatment. 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 3of 84
Proprietary confidential information © [ADDRESS_915706]-03(13.0)/Saved on: 05 Aug 2015Nam e of company: Boehringer Ingelheim 
Nam e of finished product:NA
Nam e of active ingredient:BI 695501
Protocol date:
26Apr2016Trial number:
1297.12Revision date:
Patients with prior exposure to more than 1 biologic (must not be adalimumab) will 
be excluded from this trial.
Test product(s): BI 695501, solution for subcutaneous ( s.c.) injection in single- use prefilled syringe  
(40 mg)
dose: Starting [ADDRESS_915707] administration of 80 mg BI 695501 after 
randomization, patients will receive 40 mg every other w eek.
mode of administration: Subcutaneous injection
Comparator products: US-licensed Humira, solution for s.c.injection in single -use prefilled syringe 
(40mg)
dose: Starting [ADDRESS_915708] administration of 80 mg Humira after randomization, 
patients will receive 40 mg every other w eek via a single prefilled glass syringe.
mode of 
administration:Subcutaneous injection
Duration of treatm ent: Patients are planned to be treated w ith trial medication for [ADDRESS_915709] a PASI 50 response will continue the treatment after 16 w eeks, ending at 
Week 24.
Endpoints Efficacy endpoints will be measured at Week 16 (equivalence assessment) and 
Week 24.
Primary efficacy endpoint:
Proportion of patients with a 75% reduction in Psoriasis Area and Severity 
Index ( PASI 75)response at Week 16
Secondary endpoints:
Efficacy
Proportion of patients w ith a PASI 75 response at Week 24
Mean percentage improvement in PASI at Week 16
Proportio n of patients with a sPGA ≤ 1 (clear or almost clear) at Week 16
Proportion of patients achieving a Dermatology Life Quality Index 
(DLQ I) of 0 or 1 at Week 16 
Safety
Proportion of patients with drug -related adverse events (AEs)
Safety criteria: Physical examination, vital signs (blood pressure, pulse rate, body temperature), 
12-lead electrocardiogram (ECG), laboratory tests, continuous AE monitoring ,and 
local tolerability .
Statistical m ethods: Prim ary analysis
To conclude equivalence, the 95% confidence interval ( CI)of the difference in 
PASI [ADDRESS_915710] be fully 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 4of 84
Proprietary confidential information © [ADDRESS_915711]-03(13.0)/Saved on: 05 Aug 2015Nam e of company: Boehringer Ingelheim 
Nam e of finished product:NA
Nam e of active ingredient:BI 695501
Protocol date:
26Apr2016Trial number:
1297.12Revision date:
within the equivalence limits of ± 18%. 
Secondary analysis
Forthesecondary efficacy endpoints ,point estimates (risk difference for binary 
endpoints) and CIs will be calculated, but will be interpreted in a descriptive 
manner. Safety endpoints and AESIs will be presented descriptively. Risk ratio 
together with 95% CI will be presented for the secon dary safety endpoint.
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 5of 84
Proprietary confidential information © [ADDRESS_915712]-03(13.0)/Saved on:05Aug 2015FLOW CHART
Visit11 2 3 4 5 6 7 8 9 10
WeekScreen
-4to -1Base
line
01 3 4 5 7 8 9 11 12 13 15 16 17 19 20 21 2324
EoT33
SFU2
Days-28 
to -111 1 8 22 29 36 50 57 64 78 85 92 106 113 120 134 141 148 162 169 232
Perm itted visit 
window  (days)- - 1/ +2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 + 3
Informed consent X
Assessment of 
eligibility X X
Dem ographics X
Medical history X
LAB /SAFETY ASSESSMENTS3
Infection screen: 
TB, hepatitis B 
(HBsAg, anti -
HBc), hepatitis C 
(anti-HCV), HIV X
Chest X -ray X4
TB testing (IGRA 
or [COMPANY_003] testing)[ADDRESS_915713] X X X X X X
Physical 
examination X X X X X X
Vital signs6X X X X X X
Safety Laboratory 
testsX X X X X X
12-lead ECG X X X X X
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 6of 84
Proprietary confidential information © [ADDRESS_915714]-03(13.0)/Saved on: 05 Aug 2015Visit11 2 3 4 5 6 7 8 9 10
WeekScreen
-4to -1Base
line
01 3 4 5 7 8 9 11 12 13 15 16 17 19 20 21 2324
EoT33
SFU2
Days-28 
to -111 1 8 22 29 36 50 57 64 78 85 92 106 113 120 134 141 148 162 169 232
Perm itted visit 
window  (days)- - 1/ +2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 + 3
Previous and 
concomitant 
therapy◄▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ X▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬►
Adverse events7◄▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ X▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬►
EFFICACY ASSESSMENTS3
PASI X X X X X X X X
sPGA X X X X X X X X
DLQI X X X X X X X X
 
TRIAL MEDICATION
Contact [CONTACT_12067]11X XX
12X
12X
12X
12X
12X
12
Trial medication9X X X X X X X X X X X X X
Revie w patient 
diary13 X13X13X13X13X13X13X13
Randomization10X

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 7of 84
Proprietary confidential information © [ADDRESS_915715]-03(13.0)/Saved on: 05 Aug 2015Abbreviations: ; AE=adverse event; anti -HBc=anti -hepatitis B core antibodies; anti -HCV=anti -hepatitis C antibodies; DLQI=Dermatology Life Quality I ndex; EoT=End 
of Treatment; I RT=I nteractive Response Technology; HBsAg= hepatitis B surface antigen; HIV=human immuno deficiency virus; IGRA=interferon gamma- releasing assay;  
; PASI=Psoriasis Area and Severity I ndex;  [COMPANY_003]=purified protein derivative; SFU=Safety Follow -up; sPGA=Stati c 
Physician’s Global Assessment of psoriasis; TB=tuberculosis. 
1.Patients will have to visit the site for efficacy assessments and to provide samples for /safety. For other visits ( Weeks 3 , 5, 7, 9,11, 
13, 15, 17, 19, 21 and 23 ), patients arebe allow ed to self -administer the drug at home (after training) . 
2.Patients who discontinue the trial early (also those not achieved PACI 50 at w eek 16) will, at discontinuation, have an End of Treatment (EoT) Visit 
equivalent to the Week 24assessments (except trial medication administration ). Every effort should be made for all patients to return for a Safety Follow -
up (SFU) Visit [ADDRESS_915716] drug administration . 
3.All efficacy (e.g., PASI, and sPGA ) and safety assessments will be performed by [CONTACT_229191]. 
4.Achest X -ray is to be taken at S creening. Alternatively, results from a chest X -ray taken within [ADDRESS_915717] a negative tuberculosis (TB) screenin g assessment, including a purified protein derivative ([COMPANY_003] ) skin test or interferon 
gamma -releasing assay (IGRA) (e.g., QuantiFERON®TB Gold or T -SPOT®.TB). In addition, a TB test can be performed at any time during the trial if the 
investigator considers it clinically necessary. 
6.Vital signs include measurement of bod y temperature, blood pressure, and pulse rate (all in the sitting position after a [ADDRESS_915718]). 
7.Adverse events (AEs) w ill be collected from the time of informed consent. Adverse events con tinuing at the SFU Visit must be followed to resolution or 
followed up as agreed by [CONTACT_173875]. For patients who complete the t rialor who discontinue the trial early, new AEs will be 
captured for up to [ADDRESS_915719] drug administration (SFU Visit). 
8.  
 
 
 
9.Trial medication should be administered at Day 1, with the second injection 7 days later and subsequent injections every 2 weeks thereafter (± 2 days up to
Week 14 and ± 3days from Week [ADDRESS_915720]). 
10.Randomization can occur through a randomization call or on Day 1 ( -1 /+2) through a standard randomization visit call. The Day 1 randomization or call 
will depend on the trial site procedure. Patients w ill be r
andomized to each treatment in a 1:1 ratio (BI 695501:US -licensed Humira®). For some sites,the 
registration call mightbe m ade approximatelly [ADDRESS_915721] administration of trial medication. Patients will be tentatively assigned to 
each treatment at random in a 1:1 ratio (BI 695501:US -licensed Humira®) and a position on the randomization scheme will be reserved. On Day 1 (or 
when the drug is at site), a randomization number will be assigned and patients will then be confirmed on the ra ndomization scheme and w ill receive their 
first adm inistration of trial medication according to their randomization. 
11.Interactive Response Technology (IRT) will be contact[CONTACT_676977] .
12.One or tw osyringe smight be dispensed to the patient for the self -administration at home.
13.The patient w ill com plete a diary, documenting the date and time of trial medication self -administration and any AEs experienced betw een study visits .  

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 8of 84
Proprietary confidential information © [ADDRESS_915722]-03(13.0)/Saved on:05Aug 2015TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................... 1
CLINICAL TRIAL PROTO COL SYNOPSIS ..................................................................... 2
FLOW CHART ........................................................................................................................ 5
TABLE OF CONTENTS ........................................................................................................ 8
ABBREVIATIONS ................................
................................................................................ 12
1. INTRODUCTION ............................................................................................... 15
MEDICAL BACKGROUND ............................................................................. 15 1.1
DRUG PROFILE ................................................................................................ 16 1.2
2. RATIONALE, OBJECTIVE S, AND BENEFIT -RISK ASSESSMENT .......19
RATIONALE FOR PERFOR MING THE TRIAL ......................................... 19 2.1
TRIAL OBJECTIVES ........................................................................................ 19 2.2
BENEFIT -RISK ASSESSMENT ....................................................................... 19 2.3
3. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON......................... 21
OVERALL TRIAL DESIGN AND PLAN ....................................................... 21 3.1
3.1.1 Administrative structure of the trial ................................................................. 22
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 3.2
CONTROL GROUP ................................
........................................................... 22
SELECTION OF TRIAL P OPULATION ....................................................... 22 3.3
3.3.1 Main diagnosis for trial entry ............................................................................ 23
3.3.2 Inclusion criteria ................................
................................................................. 23
3.3.3 Exclusion criteria ................................................................................................ 24
3.3.4
Removal of patients from therapy or assessments........................................... 25
Removal of individual patients ............................................................................. 25 [IP_ADDRESS]
Discontinuation of the trial by  [CONTACT_456] ........................................................... 26 [IP_ADDRESS]
4. TREATMENTS ................................................................................................... 27
INVESTIGATIONAL TREATMENTS ........................................................... 27 4.1
4.1.1 Identity of the Investigational Medicinal Products.......................................... 27
4.1.2 Selection of doses in the trial .............................................................................. 28
4.1.3 Method of assigning patients to treatment groups ........................................... 28
4.1.4 Drug assignment and administratio n of doses for each patient ...................... 29
4.1.5 Blinding and procedures for unblinding ........................................................... 30
Blinding................................
................................................................................. 30 [IP_ADDRESS]
Unblinding and breaking the code ........................................................................ 30 [IP_ADDRESS]
4.1.6 Packaging, labelling, and re- supply ................................
................................... 31
4.1.7 Storage conditions ............................................................................................... 31
4.1.8 Drug accountability ............................................................................................. 31
OTHER TREATMENTS, EM ERGENCY PROCEDURES, 4.2
RESTRICTIONS ................................................................
................................ 32
4.2.1 Other treatments and emergency procedures .................................................. 32
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 9of 84
Proprietary confidential information © [ADDRESS_915723]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].2.2 Restricti ons.......................................................................................................... 32
Restrictions on diet and life sty le.......................................................................... 34 [IP_ADDRESS]
Restrictions regarding women of childbearing potential ...................................... 34 [IP_ADDRESS]
Restrictions regarding male participants of reproductive potential ...................... 34 [IP_ADDRESS]
TREATMENT COMPLIANCE ........................................................................ 35 4.3
5. VARIABLES AND THEIR ASSESSMENT .................................................... 36
TRIAL ENDPOINTS .......................................................................................... 36 5.1
5.1.1 Primary Endpoint ............................................................................................... 36
5.1.2 Secondary Endpoints .......................................................................................... 36
ASSESSMENT OF EFFICA CY................................
........................................ 37 5.2
5.2.1 PASI ...................................................................................................................... 37
5.2.2 Static Physician’s Global Assessment ............................................................... 38
5.2.3 Dermatology Life Quality Index ................................
........................................ 39
ASSESSMENT OF SAFETY ............................................................................. 40 5.3
5.3.1 Physical examination .......................................................................................... 40
5.3.2 Vital Signs ................................................................
............................................ 40
5.3.3 Safety laboratory parameters ............................................................................ 41
5.3.4 Electrocardiogram .............................................................................................. 43
5.3.5 Other safety parameters..................................................................................... 43
Local tolerability ................................
................................................................... 43 [IP_ADDRESS]
5.3.6 Assessment of adverse events ............................................................................. 43
Definitions of AEs ................................................................................................ 43 [IP_ADDRESS]
Adverse event collection and reporting ................................................................ 46 [IP_ADDRESS]
 
APPROPRIATENESS OF M EASUREMENTS .............................................. 52 5.7
6. INVESTIGATIONAL PLAN ............................................................................. 53
VISIT SCHEDULE ............................................................................................. 53 6.1
DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS ................. 54 6.2
6.2.1 Screening and run -in period(s) .......................................................................... 54
6.2.2 Treatment period ................................................................
................................ 55
6.2.3 Follow -up Period and Trial Completion ........................................................... 56

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 10of 84
Proprietary confidential information © [ADDRESS_915724]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
............................................................................................................................... 58
STATISTICAL DESIGN - MODEL ................................................................. 58 7.1
NULL AND ALTERNATIVE HYPOTHESES ............................................... 58 7.2
PLANNED ANALYSES ..................................................................................... 58 7.3
7.3.1 Primary endpoint analyses ................................................................................. 59
7.3.2 Secondary endpoint analyses ............................................................................. 60
Secondary  efficacy  endpoints ............................................................................... 60 [IP_ADDRESS]
Secondary  Safet y Endpoints ................................
................................................. 60 [IP_ADDRESS]
7.3.[ADDRESS_915725] access to source data and documents
..................................................... 68
8.3.3 Storage period of records ................................................................................... 68
EXPEDITED REPORTING 
OF ADVE RSE EVENTS .................................. 68 8.4
STATEMENT OF CONFIDE NTIALITY AND PATIENT PRIVACY ........ 68 8.5
8.5.1 Collection, storage and future use of biological samples and corresponding 
data ................................
....................................................................................... 69
TRIAL MILESTONES ....................................................................................... 69 8.6
9. REFERENCES .................................................................................................... 71
PUBLISHED REFERENCES ............................................................................ 71 9.1
UNPUBLISHED REFERENC ES...................................................................... 73 9.2
10. APPENDICES ................................
..................................................................... 74
CLINICAL EVALUATION OF LIVER INJURY .......................................... 74 10.1

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 11of 84
Proprietary confidential information © [ADDRESS_915726]-03(13.0)/Saved on: [ADDRESS_915727] PARTY 10.3
BLINDING ................................
.......................................................................... 80
11. DESCRIPTION OF GLOBA L AMENDMENT(S) ......................................... 84
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 12of 84
Proprietary confidential information © [ADDRESS_915728]-03(13.0)/Saved on: [ADDRESS_915729] Hematocrit 
HCV hepatitis C virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICH International Co uncil forHarmoni zation
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IgG1 immunoglobulin G1
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 13of 84
Proprietary confidential information © [ADDRESS_915730]-03(13.0)/Saved on: [ADDRESS_915731] Patient Drug Discontinuation
MedDRA Medical Dictionary  for Drug Regulatory  Activities
MI multiple imputation
MTX methotrexate
nAb neutralizing antibod y
NRI non-responder imputation
NSAID non-steroidal anti -inflammatory  drug
PASI Psoriasis Area and Severity  Index
PASI 50 50% reduction in Psoriasis Area and Severit y Index
PASI 75 75% reduction in Psoriasis Area and Severit y Index
[COMPANY_003] purified protein derivative
PPS per-protocol set
PUVA
psoralen with ultraviolet A light
RA rheumatoid arthritis
RBC red blood cell
REP residual effect period, after the last dose of medication with measureable 
drug levels or pharmacodynamic effects still likely to be present
SAE serious adverse event
SAF safet y analysis set
s.c. subcutaneous
SFU Safety  Follow -up
SOP standard operating procedure (s)
SPC summary  of product characteristics
sPGA static Physician’s Global Assessment
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB tuberculosis
Th17 T helper [ADDRESS_915732] upper limit of normal
US-PI [INVESTIGATOR_265299] A light

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 14of 84
Proprietary confidential information © [ADDRESS_915733]-03(13.0)/Saved on: 05 Aug 2015UVB Ultraviolet B light
WHO World Health Organization
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 15of 84
Proprietary confidential information © [ADDRESS_915734]-03(13.0)/Saved on: [ADDRESS_915735] prevalent immune -mediated skin disease that affects 1% to 3% of the 
population worldwide, with an equal sex distribution. The most common form of the disease, 
termed “ plaque psoriasis ”, is observed in more than 80% of psoriasis patients and is 
characterized b y erythematous scal y plaques, t ypi[INVESTIGATOR_676964], knees, scalp ,and buttocks. 
Twenty -five percent of patients have moderate to severe disease , with considerable negative 
impact on their 
psychosocial and economic status ( R11-1259
).Psoriasis causes a high degree 
of morbidity  and decreased quality  of life, largely  due to flares and disfiguring lesions in 
visible areas of the skin, sy stemic manifestations ,and drug -related side effects.
Histological examination of psoriatic plaques reveals keratinocy tehyperproliferation ,with 
parakeratosis and elongation of rete ridges, increased angiogenesis and dermal infiltration by
[CONTACT_676978], including T -cells, neutrophils, macrophages and dendritic cells. Psoriasis 
is probably  a complex multifactorial dis ease in which various environmental triggers (e.g., 
trauma, stress, infections and drugs) promote, in geneticall y predisposed individuals, an 
exaggerated and poorl y controlled immuno -inflammatory  response in the skin which leads to 
excessive keratinocy te proliferation.
It is increasingly recognized that psoriasis is more than a skin disease, with up to 30% of 
patients having joint inv olvement and a high correlation between psoriasis and obesity , 
diabetes, depression, metabo lic sy ndrome ,and cardiovascular risk ( R15-1393 ).
Current Treatment Options
Psoriasis treatment varies with the extent and severity  of the disease. Current treatment 
options include topi[INVESTIGATOR_12969] (topi[INVESTIGATOR_11930], vitamin D analogues, anthralin, 
topi[INVESTIGATOR_22775], calcineurin inhibitors, salicy lic acid, coal tar , and moisturizers), 
phototherap y,and s ystemic treatments. Topi[INVESTIGATOR_676965] y used for more 
localized and mild forms of psoriasis. Exposure of skin to artificial ultraviolet A or B light, 
either alone or in combination with medications such as psoralen, has also been shown to be 
quite effective for mild to moderate psoriasis. Fo r more resistant or moderate to severe 
psoriasis, sy stemic oral or parenteral medications are used for better efficacy . Systemic oral 
medications such as methotrexate (MTX), cy closporine and retinoids have traditionally  been 
the most commonl y prescribed drugs for moderate to severe psoriasis. Over the last few 
years, the introduction of biologic immunosup pressive drugs, such as anti
-tumor necrosis 
factor agents (TNFs), anti- interleukin (IL)12/[ADDRESS_915736] been unable to tolerate or are resistant to other 
systemic psoriasis therapi[INVESTIGATOR_014].
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 16of 84
Proprietary confidential information © [ADDRESS_915737]-03(13.0)/Saved on: 05 Aug 2015DRUG PROFILE 1.2
The mechanisms of action of anti-TNF agents in psoriasis, including H umira , are not fully  
understood and may  vary in different disease settings. 
TNF -α antagonists enhance T helper 17 cells (Th17) function, but suppress forkhead box P3
(FoxP3) + Tregs (regulatory  T cells) in the skin in the murine psoriasis- like model 
(R16-0235).
Humira (adalimumab) has rec eived regulatory  approval for psoriasis in the US , the EU, and
many  other countries ( R15-5978 and R16-0358). BI 695501 i s being developed as a proposed 
biosimilar to US -licensed Humira and EU -approved Humira.
Adalimumab (Humira) has a generall y favorable clinica l safet yprofile, and is not associated 
with AEs that would suggest a high risk to subjects participa ting in this trial. I n patients 
treated with Humira, most common adverse reactions (inc idence >10%) include infections 
(e.g.,upper respi[INVESTIGATOR_696] , sinusitis) ,injection site reactions, hea dache, rash, abdominal pain, 
musculoskeletal pain, nausea, and vomiting. Allergic reactions (e.g., allergic rash, 
anaph ylactoid reaction, fixed drug reaction, non- specified drug reaction, urticaria) have been 
observed in appr oximately  1% of patients.
Cases of hepatitis B virus (HBV) reactivation have been reported in patients receiving
anti-TNF therap y. Some cases have been fatal, the majority of which were in patients
concomitantly  receiving other immunosuppressive medications.
Tuberculosis (TB) reactivation or new TB infections have been observed in patients receiving 
Humira and other TNF -inhibitors, including patients who ha d previousl y received treatment 
for latent or active TB.
BI 695501 is a monoclonal antibody  being de veloped as a proposed biosimilar to the 
TNF -alpha blocker US -licensed and EU- approved Humira®(adalimumab). Adalimumab is a 
recombinant human ized monoclonal immunoglobulin (Ig) G 1antibody  specific to human 
TNF -alpha. Humira binds specificall y to TNF -alpha (not to TNF -beta) and blocks its 
interaction with the p55 and p75 cell surf ace TNF receptors. It has human- derived heavy  and 
light chain variable regions and human immunoglobulin (Ig)
G1:k (kappa) constant regions 
and is produced in a mammalian cell expression sy stem ( R15-
5978 andR16-0358).
The preclinical studies that support the clinical program include : 
  
 
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 17of 84
Proprietary confidential information © [ADDRESS_915738]-03(13.0)/Saved on: [ADDRESS_915739] s1297.1 and 1297.8
(U13-1096-01 and c03070713 ) .ThePKsimilarity of BI 695501 to US-licensed Humira and 
EU-approved Humira was demonstrated in a healthy  volunteers study  using the final
commercial formulation ( c03070713) . Single s.c.doses of [ADDRESS_915740] to safet y, 
tolera bility ,and immunogenicity .
Overall, the adverse events ( AEs)seen in [ADDRESS_915741] t rials for BI 695501 and both 
EU-approved Humira andUS-licensed H umira were in line with the known safet y profile 
presented in the US prescribing information for Humira ( R15- 5978 ) and in the summary  of 
product characteristics (SPC) for EU -approved Humira ( R16-0358).
Aphase III trial(1297.2) in patients with moderate to se vere rheumatoid arthritis ( RA)is 
ongoing . A total of 645 patients with moderate to severe RA were included in the study  and 
are being treated with either BI 695501 or US -licensed Humira. T he observed blinded AE
profile revealed no unexpected safet y findings and showed no clinicall y relevant safet y 
concerns.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 18of 84
Proprietary confidential information © [ADDRESS_915742]-03(13.0)/Saved on: 05 Aug 2015For further detailed description of the BI 695501 profile please refer to the current
‘Investigator’s Brochure’ (IB) (c01843589 )and for the US-licensed Humira to the United 
States Package Insert (US-PI) (R15-5978 ).
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 19of 84
Proprietary confidential information © [ADDRESS_915743]-03(13.0)/Saved on: [ADDRESS_915744] the data is provided in Section 5.
BENEFIT -RISK ASSESSMENT 2.3
Participation in this study may help to generate future benefit for larger groups of patients
with psoriasis .
Patient risk will be minimized in this trial by  [CONTACT_36127].
Adverse events, bod y temperature, vital signs, electrocardiograms ( ECGs) and safety  
laborator ies as well as immunogenicit y will be monitored at different time points du ring the 
trial and d uring the long term safet y follow -up period up to [ADDRESS_915745] 
administration of trial medication.
Although rare, a potential for drug -induced liver injury (DILI) is under constant surveillance 
by [CONTACT_23274]. Therefore, this trial requires timely  detection, evaluation, and 
follow -up of laboratory  alterations in selected liver laborator y parameters to ensure patients’
safet y,see also S ection [IP_ADDRESS] .
All safet y aspects w illbe regularl y monitored b y both the Sponsor and a Contract Research 
Organization ( CRO )during the Medical Qualit y Review Meetings.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 20of 84
Proprietary confidential information © [ADDRESS_915746]-03(13.0)/Saved on: 05 Aug 2015To avoid a risk of reactivating TB and other infections, TB tests (interferon -gamma release 
assay  [IGRA] or purified protein derivative [ [COMPANY_003]] skin test ), Hepatitis B surface a ntigen
(HBsAg; qualitative), Hepatitis B a ntibody (anti-HBc; qualitative), Hepatitis C a ntibodies 
(Anti- HCV; qualitative), human immunodeficiency virus (HIV) -1 and HIV -2 antibody  (at the 
discretion of the investigator where clinicall y indicated )
will be performed to exclude 
subjects who test positive. Risk to subjects will also be minimized in this trial by 
[CONTACT_36127].
In the controlled portions of clinical trials of some TNF-inhibitors, including Humira , more 
cases of malignancies have been observed among TNF -inhibitor-treated adult patients 
compared to control -treated adult patients. Therefore, a possi bly increased risk for the 
development of malignancies cannot be excluded.
TNF -antagonists including Humira have been associated ,in rare instances ,with new onset o r
exacerbation of clinical symptoms and / or radiographic evidence of central nervous s ystem 
demy elinating disease ,including multiple sclerosis and optic neuritis, and peripheral 
demy elinating disease including Guillain -Barre s yndrome. Prescribers should exercise 
caution in considering the use of Humira in patients with pre -existing or recent- onset central 
or peripheral nervous s ystem demy elinating disorders.
To minimize the risks, patients with a significant disease other than psoriasis will be excluded 
from the trial participation.
The PK similarity  of BI 695501 to US -licensed and EU -approved Humira was established in 
the phase I trial 1297.8 ( c03070713 ). Additionally , there w
ere no notable differences with 
respect to safet y, tolerability ,and immunogenicity between BI 695501 to US- licensed and 
EU-approved Humira in this phase I trial ,and the dose of 40 mg BI 695501 was safe and well 
tolerated in male healthy  volunteers. T he observed blinded AE profile in the phase III trial 
1297.2 ( c02158186 )revealed no unexpected safety  findings and showed no clinically  
relevant safet y concerns. The review of safet y data in 1297.2 trial by  [CONTACT_115376] (IDMC) todate has not suggested an y clinicall y relevant differences 
in safet y profile between Humira and BI 695501.
There were no clinicall y relevant 
findings with respect to clinical laboratory  evaluation, vital 
signs, ECGs, or injection site reactions. Based on extensive preclinical, analy tical, functional ,
and toxicological testing carried out prior to initiation of this trial, and the Phase Idata 
described above, BI 695501, as a proposed biosimilar to Humira , is expected to show a
similar efficacy , safety , immunogenicit y and PK profile 
in patients with psoriasis .
Patients not achieving at least PASI 50 (patients showing lack of efficacy ), will not continue 
receiving their treatment up to Week [ADDRESS_915747]. 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 21of 84
Proprietary confidential information © [ADDRESS_915748]-03(13.0)/Saved on: [ADDRESS_915749] signed the informed consent. Patients
suitable after screening will be eligible to participate in the 2 4-week treatment period and will 
be randomized at a ratio of 1:1 in a blinded fashion to 1of 2 treatment arms ( BI 695501 or
US-licensed Humira ) shown in Figure 3.1: 1.
After W eek [ADDRESS_915750] a 50% reduction in Psoriasis Area and 
Severity  Index (PASI 50)response will continue the trial receiving their randomized 
treatment up to W eek [ADDRESS_915751] PASI 50 (or who discontinue 
the trial earl y), will not be treated with the stud y drugs, but onl y followed up for safety . 
Patients will undergo visits and trial procedures as shown in the Flow C hart.
All patients who receive at least [ADDRESS_915752] a Safety  Follow -up visit 
10 weeks after the las t dose of trial medication .
Every  effort should be made for all patients who complete the 24-week treatment period or 
who discontinue the trial earl y (and do not withdraw their consent), to return for a safet y 
follow -up visit [ADDRESS_915753] administration of trial medication.
Figure 3.1: 1 Trial design

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 22of 84
Proprietary confidential information © [ADDRESS_915754]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].1.1 Administrative structure of the trial
The trial is sponsored b y Boehringer Ingelheim International (BI).
CRO will perform Project Management, Clinical Field Mo nitoring, Medical Monitoring,
Data Management , and Statistical Evaluation according to CRO Standard Operating 
Procedures (SOPs) . A list of responsible persons and relevant local information can be found 
in the Investigator Site File (ISF).
A Coordinating Investigator [INVESTIGATOR_676966]. Tasks and responsibilities will be defined in a 
contract. Relevant doc umentation on the participating (Principal) Investigators and o ther 
important participants, includ ing their curricula vitae, will be filed in the electronic trial 
master file.
Boehringer Ingelheim has appointed a Trial Clinical Monitor, responsible for coordinating all 
required activities, in order to 
manage the trial in accordance with applicable regulations and applicable Boehringer 
Ingelheim and CRO SOPs,
direct the clinical trial team in the preparation, conduct, and reporting of the trial,
ensure appropriate oversight of vendors .
A list of 
responsible persons and relevant local information can be found in the I SF.
A central laboratory  service and an Interactive Response Technology (IRT)vendor swill be 
used in this trial. Details will be provided in the IRT Manual and Central Laboratory  Man ual, 
available in the ISF.
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 3.2
CONTROL GROUP
The current trial is being performed to establish an equivalence of efficacy  between BI 
695501 and US -licensed Humira in patients with active moderate to severe chronic plaque 
psoriasis.
This is a randomized, double -blind, parallel arm, multiple dose, active comparator trial of BI 
695501 and US -licensed Humira with a planned 24 -week treatment period followed b y a 10-
week safet y follow up , in patients with active moderate to s
evere chronic plaque psoriasis.
The treatment groups will be blinded throughout the whole trial , to minimize any  bias that 
could be introduced b y knowledge of the treatment by  [CONTACT_676979].
SELECTION OF TRIAL P OPULAT ION 3.3
A total of approximately  300 patients is planned to be randomized in the current trial. 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 23of 84
Proprietary confidential information © [ADDRESS_915755]-03(13.0)/Saved on: 05 Aug 2015A log of all patients enrolled into the trial (i.e.,who have signed informed consent) will be 
maintained in the I SF at the investigational site irrespective of whether they  have been treated 
with investigational drug or not.
3.3.[ADDRESS_915756] 2 months 
with no meaningful changes in morphology  or significant flares, def ined as ≥ 10% body
surface area (BSA) involvement, Psoriasis Area and Severity  Index (PASI ) score ≥ 12 and 
static Physician’s Global Assessment (sPGA) score ≥ 3.
Please refer to S ection 8.3.1 (Source Documents) for the documentation requi rements 
pertaining to the inclusion and exclusion criteria.
3.3.2 Inclusion criteria
1.Males and females aged ≥ 18 to < [ADDRESS_915757] a diagnosis of moderate to severe 
chronic plaque psoriasis (with or without psoriatic arthritis) for at least [ADDRESS_915758] administration of stud y drug (a self-reported diagnosis confirmed by  [CONTACT_676980]), and which has been stable for the last 2 months with no 
changes in morphology  or significant flares at both Screening and Baseline 
(Randomization):
a.involved BSA ≥ 10% and
b.PASI score ≥ 12 and
c.sPGA score of ≥ 3.
2.
Participants of reproductive potential (childbearing potential1)must be willing and able 
to use highl y effective methods of birth control per International Council for
Harmonization (ICH)M3(R2) that result in a low failure rate of less than 1% per year
when used consistentl y and correctly during the trial and for [ADDRESS_915759] of contraception methods 
meeting these criteria is provided in the Section [IP_ADDRESS] and patient information.
3.Signed and dated written informed consent in accordance with Good Clinical Practice
(GCP ) and local legislation prior to admission to the trial.
4.Patients who are candidates for s ystemic therapy .
                                                
1Women of childbearing potential are defined as:
- having experienced menarche and 
- not postmenopausal (12 months with no menses without an alternative medical cause) and 
- not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral 
salpi[INVESTIGATOR_1656]).
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 24of 84
Proprietary confidential information © [ADDRESS_915760]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].3.3 Exclusion criteria
1. A ctive ongoing inflammatory  diseases other than psoriasis that might confound trial 
evaluations according to investigator’s judgment .
2.Previous treatment with more than [ADDRESS_915761] 6 months of screening will be permitted
3. Patients with a significant disease other than psoriasis and/or a significant uncontrolled 
disease (such as, but not limited to, nervous system, renal, hepatic, endocrine , 
hematological, autoimmune or gastrointestinal disorders). A significant disease is defined 
as a disease which, in the opi[INVESTIGATOR_871], may  (i) put the patient at risk 
because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause 
concern regarding the patient's ability  to participate in the trial. 
4.Major surgery  (major accor ding to the investigator’s assessment) performed within 
12weeks prior to randomization or planned within 6months after screening, e.g. ,total 
hip replacement.
5.Any documented active or suspected malignancy  or history  of malignancy  within [ADDRESS_915762] or wish to continue the intake of restricted medications (see 
Section [IP_ADDRESS]) or an y drug considered likel y to interfere with the safe conduct of the 
trial.
7.Currently  enrolled in another investigational device or drug study , or less than 30 day s 
since ending another i
nvestigational device or drug stud y(s), or receiving other 
investigational treatment(s) .
8.Chronic alcohol or drug abuse or an y condition that, in the investigator’s opi[INVESTIGATOR_1649], makes 
thepatient an unreliable study  subject or unlikel y to complete the trial.
9.Women who are pregnant, nursing, or who plan to become pregnant during the course of 
this study  or within the period at least 6 months following completion or discontinuation 
from the trial .
10. F orms of psoriasis (e.g., pustular, ery throdermic and guttate) other than chronic plaque 
psoriasis. Drug -induced psoriasis (i.e., new onset or current exacerbation from e.g., 
beta-blockers or lithium).
11.Primary  or secondary  immunodeficiency  (history  of, or currentl y active), including 
known history  of HIVinfection or a positive HIV test at screening (per the investigator 
discretion and where mandated b y local authorities).
12.Known chronic or relevant acute tuberculosis,; IGRA TB test or [COMPANY_003] skin test will be 
performed ac cording to the labelling for Humira . If the result is positive, patients may  
participate in the stud y if further work up (according to local practice/guidelines) 
establishes conclusivel y that the patient has no evidence of active tuberculosis. I f latent 
tuberculosis is confirmed, then treatment must have b een initiated before randomization 
and continued accord ing to local country  guidelines2.
                                                
2For [LOCATION_013]: patients with positive IGRA TB test or [COMPANY_003] skin test will be excluded from the study 
participation.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 25of 84
Proprietary confidential information © [ADDRESS_915763]-03(13.0)/Saved on: 05 Aug 201513.Known clinicall y significant coronary  artery  disease, significant cardiac arrhy thmias, 
moderate to severe congestive heart failure ([LOCATION_001] Heart Association Classes III or 
IV) or interstitial lung disease observed on chest X- ray. 
14.History  of a severe allergic reaction, anaphy lactic reaction ,or hypersensitivity  to a 
previously  used biologic aldrug or its excipi[INVESTIGATOR_840].
15. P ositive serology  for hepatitis B virus ( HBV )or hepatitis C virus (HCV). 
16. Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit; patients 
who are expecting to receive an y live /attenuated virus or bacterial vaccinations during the 
trial or up to [ADDRESS_915764] dos e of trial drug .
17.Any treatment (including biologic therapi[INVESTIGATOR_014]) that, in the opi[INVESTIGATOR_871], may  
place the patient at unacceptable risk during the trial.
18.Known active infection of an y kind (excluding fungal infections of nail beds), an y major 
epi[INVESTIGATOR_36116] ( i.v.)
anti-infectives within 4 weeks of the Screening Visit or completion of oral anti- infectives 
within 2 weeks of the Screening Visit.
19. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times upper 
limit of normal (UL N)at Screening. 
20.
Hemoglobin < 8.0 g/dL at Screening. 
21.Platelets < 100,000/µL at Screening.
22.Leukocy te count < 4000/µL at Screening.
23.Creatinine clearance < 60 mL /min/1.73 m2at Screening.
24.Patients with a history  of any  clinically  significant adverse reaction to murine or chimeric 
proteins, or natural rubber and latex, including serious allergic reactions.
3.3.4 Removal of patients from therapy or assessments
Removal of individual patients [IP_ADDRESS]
All patients have the right to withdraw from the study  at any  time without the need to justify  
their decision. The investigator has the right to remove patients from the study  for 
non-compliance or other reasons . 
An individual patient is to be withdrawn from trial treatment if:
The patient decides to discontinue participation in the trial by  [CONTACT_28475]. In 
this case, no more investigations will be performed.
The patient needs to take concomitant drugs that interfere with the investigational product 
or other 
trialmedication.
Lack of efficacy defined as PASI 50not reached at W eek 16.
Development of a toxicity  or adverse event which warrants BI 695501/Humira
discontinuation including but not limited to serious adverse events (SAEs )or suspected 
unexpected serious adverse reactions ( S[LOCATION_003]Rs ).
The patient has an AE that is categorized as a serious infection. A serious infection is
defined as an infection requiring i.v. antibiotics or meet ingthe regulatory  definition of a 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 26of 84
Proprietary confidential information © [ADDRESS_915765]-03(13.0)/Saved on: 05 Aug 2015SAE (including, but not limited to, sy stemic fungal infections, HIV, HBV, HCV, TB, 
infected joint prosthesis) .
The patient can no longer be treated with trial medication for other medical reasons ( such 
assurgery , adverse events, other dise ases, or pregnancy ).
If the trial treatment is not in the patient’s best interest at the investigator’s discretion. 
(e.g. severe worsening of psoriasis). The patient will be discontinued from the trial to 
receive treatment as deemed appropriate b y the investigator .
The patient has repeatedly  shown to be non -compliant with important trial procedures 
and, in the opi[INVESTIGATOR_35915] , is not willing or 
able to adhere to the trial requirements in the future.
If a pat ient permanentl y discontinues trial medication for an y reason (including lack of 
efficacy ), every effort should be made to 
have the patient return for a safety  follow -up visit 
[ADDRESS_915766] dose of trial medication.
Given the patient’s agreement, the patient will undergo the procedures for earl y treatment 
discontinuation and follow -up as outlined in the Flow Chart (Safet y Follow -up [ SFU]visit)
and S ection 6.2.3.
For all patients the reason for withdrawal (e.g.,AEs) must be recorded in the electronic C ase 
Report Form (e CRF ). These data will be included in the trial database and reported.
Discontinuation of the trial by  [CONTACT_941] s ponsor [IP_ADDRESS]
Boehringer Ingelheim reserves the right to discontinue the trial overall or at a particular trial 
site at any  time for reasons including but not restricted to :
1.Failure to meet expected enrol mentgoals overal l orat a particular trial site
2.Emergence of an y efficacy /safet y information invalidating the earlier positive benefit -risk 
assessment that could significantly affect the continuation of the trial
3.Violation of GCP, the Clinical Trial Protocol (CTP), or the con
tract impairing the 
appropriate conduct of the trial.
The Investigator / the trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except in case of the third reason).
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 27of 84
Proprietary confidential information © [ADDRESS_915767]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. TREATMENTS
INVESTIGATIONAL TREATMENTS 4.1
The trialmedication will be pr ovided b y BI.
4.1.1 Identity of the Investigational Medicinal Products
BI 695501 and US -licensed Humira will be used in this study . Details of the trial medication
are provided in Tables 4.1.1: 1 , and 4.1.1: 2.
Table 4.1.1: [ADDRESS_915768]
Substance: BI 695501
Pharm aceutical formulation: Solution for injection in prefilled syringe
Source: BI Pharma GmbH & Co. KG, [LOCATION_013]
Unit strength: 40 mg / 0.8 mL
Posology 80 mg (loading dose) on Day  1/ Week 0 ,
40 mg every other we ek from Week 2 to W eek 23
Route of administration: Subcutaneous injection
Table 4.1.1: [ADDRESS_915769]
Substance: US-licensed Humira (adalimumab)
Pharm aceutical formulation: Solution for injection in prefilled syringe
Source: [COMPANY_013] Inc.
Unit strength: 40 mg / 0.8 mL or 40 mg / 0.4 mL
Posology 80 mg (loading dose) on Day  1/ Week 0 ,
40mg every other week from Week 1 to W eek 23
Route of administration: Subcutaneous injection
BI 695501 prefilled s yringe will be provided assterile, preservative -free, non -pyrogenic, 
single -use prefilled glass sy ringes containing 40 mg of BI 695501 per 0.8 mL. One sy ringe 
will be used per injection except for Week 0 /Day  1, at which 2 syringes (80 mg) will be used . 
The needle cap of the s yringe contains dry , natural rubber.
US-licensed Humira will be provided in sterile, preservat ive-free, non- pyrogenic, single -use, 
prefilled glass syringes containing 40 mg of adalimumab per 0.8 mL or 0.4 mL of solution. 
One s yringe will be used per injection except for Week 0 /Day 1, at which 2 syringes 
(80mg) will be used.
Any unused product or waste material will be disposed of in accordance with local 
requirements.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 28of 84
Proprietary confidential information © [ADDRESS_915770]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].1.2 Selection of doses in the trial
In the US and EU, adalimumab (Humira) has received health authorit y approval for the 
treatment of RA, Crohn’s disease, plaque psoriasis, psoriatic arthritis, ank ylosing spond ylitis,
juvenile idiopathic arthritis and Hidradenitis suppurativa . The doses of BI 6955 01 and 
Humira selected for this trial are identical due to the similarity  of both compounds (an initial 
dose of 80 mg s.c. injection followed 1 week later and subsequentl y ever y other week b y 40 
mg)andare the doses that were used to assess the efficacy of the originator compound and 
are as per Humira label .
4.1.[ADDRESS_915771] met all the inclusion criteria and none of the 
exclusion criteria, a pre
-treatment call will be made using the IRTsystem. Screen failure 
patients may  be rescreened once based on investigator judgment and prior permission from 
medical monitor of the study .
The registration call will depend on the trial site procedure. The process for treatment 
assignment might be different depending on the country and respective trial medication 
shippi[INVESTIGATOR_79762]. I n countries where trial medication needs to be sent to sites in advance 
due to long shippi[INVESTIGATOR_79762] (e.g., cross border shipments), trial medication will be 
provided to the sites in advance and patients will be assigned treatment on Day  1. For 
countries where trial medication can be provided on short noti ce (short shippi[INVESTIGATOR_8071]) a 
registration call will be made as described below and trial medication will be shipped. The 
registration call might be made within [ADDRESS_915772] admi nistration of trial 
medication. Eligible patients will then be confirmed to t
he randomization scheme on Day  1 
(or when the drug is a t site), according to their randomization.
Patients will be randomized to each treatment in a 1:1 ratio (BI 695501 or US-sourced 
Humira) at Visit 2.
Initial randomization will be stratified according to prior exposure to a biologic agent (y es / 
no).
Randomization will be performed in a blinded fashion via IRT.Patients will be randomized 
sequentially  (the lowest sequentially  available randomization number).
Each s yringe of trial medication will be labeled with the tri al code and a unique medication 
identification number. The I RT s ystem will be used for th e randomization, allocation ,and 
supply  of trial medication throughout the stud y. The I RT will assign each patient a unique 
medication number for each drug administration. Details of the IRT s ystem will be provided 
in the I SF.
Access to the randomization code will be controlled and documented. All persons directl y
involved in the condu ct and anal ysis of the trial will have no access to the treatment 
allocatio n prior to final database lock.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 29of 84
Proprietary confidential information © [ADDRESS_915773]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].1.4 Drug assignment and administration of doses for each patient
Each patient will receive 80 mg of BI 695501 or US- licensed Humira at t he Baseline Visit
(Day  1, Week 0) followed by  40 mg of BI 695501 or US -licensed Humira 1 week later, and 
then 40 mg of BI 695501 or US -licensed Humira every  other week until Week 16 (primary  
endpoint). 
After Week 16 (Day  112), patients achieving at least a PASI 50 respons e will continue 
receiving their randomized treatment (40 mg BI 695501 or Humira every  other week ) until 
Week [ADDRESS_915774] -administration 
assessments of an y reaction would not be compromised by [CONTACT_676981] y. The location for the trial medication injection will be the lower abdomen (excluding 
a 2-inch [5 -cm] area around the navel) and upper thigh. A different injection site should be 
selected for each injection ( at least 1 inch [2.5 cm] away  from the previous site).
For the duration of the trial, trial medication will be administered either at the trial site by  
[CONTACT_676982], or at home b y the patients themselves. At all designated site visits 
(Weeks 0 and 1), the patient must administer BI 695501 while at the trial site. Between 
designated site visits (Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 ), the patient may  choose 
to come to the site to self-inject the trial medication with the support of s uitably  qualified, 
designated trial site personnel or the patient may self-inject the trial medication at home.
Patients will be instructed to accuratel y record the dates and times of dosing, problems 
encountered with dosing, the occurrence of an y AEs, t
heuse of concomitant therapi[INVESTIGATOR_014], and 
the prefilled s yringe storage conditions on the provided diary  cards between the trial site 
visits.
For self -administration, h andling and administration of trial medication will be described in 
detail in the handling inst ructions . Cool bags and handling instructions will be provided to the 
patient (refer to the ISF).
In case of implementation of the third -party blinded procedure , for the duration of the trial, 
BI 695501 /US-sourced Humira will be admini stered b y a dedicated trial personnel 
(designated unblinded person will administer the drug to patients but will not be involved in 
any assessment of safet y or efficacy ), either at the site or at the patient’s home. These trial 
personnel will be allowed to perform dru g administrations and home visits only  after suitable 
training has been received and they  are considered to be qualified to perform the 
subcutaneous injections and the home visits.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 30of 84
Proprietary confidential information © [ADDRESS_915775]-03(13.0)/Saved on: [ADDRESS_915776] injection (Visit 2), the patient will remain at the clinic al site for at least [ADDRESS_915777] this time point.
In the event of an anaph ylactic or ot her serious hy persensitivity  reaction, the administration 
of trial medication will be discontinued immediately, the patient will be discontinued from 
the trial and appropriate therap y will be initiated.
4.1.5 Blinding and procedures for unblinding
Blinding [IP_ADDRESS]
This is a double -blind trial , therefore patients, Investigator s and every one involved in trial 
conduct (except the trial personnel adm inistering the trial medication –
third -party  blinding) in
this double -blind trialwill remain blinded with regard to the random izedtreatment 
assignments until after the final database lock.
The randomization code will be kept secret by  [CONTACT_21637].
Bioanal ytics will not disclose the randomization code or the results of their measurements 
until the trialis officially unblinded.
It is planned to conduct the study  using 0.[ADDRESS_915778]- party  blinding, where the study  drug will be 
administered to the patients by  [CONTACT_676983] (seeAppendix 10.[ADDRESS_915779] party  blinding procedure ).
The secondary  packaging (boxes containing s yringes) will be identical for both BI 695501 
and Humira ,allowing the blinding of the site pharmacy .
Unblinding and breaking the code [IP_ADDRESS]
Emergency  unblinding will be available to the Investigator via IRT . It must only  be used in
an emergency situation when the identity  of the trial drug must be known to the Investigator
in order to provide appropriate medical treatment or otherwise assure safety  of trial 
participants. If unblinding is required in the interest of the safet y of a patient, and time 
allows, the investigator will discuss the matter with the Medical Advisor be fore unblinding 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 31of 84
Proprietary confidential information © [ADDRESS_915780]-03(13.0)/Saved on: 05 Aug 2015whenever possible. If the code i s broken for a patient (via the IRT) the sponsor must be 
informed immediately . The reason for unblinding must be documented in the source 
documents and appropriate eCRF page along with the date and the initials of the person who 
broke the code.
Due to the requirements to report S[LOCATION_003]Rs, it may be necessary  for a representative from the 
BI Pharmacovigilance group to access the randomiz ation code for individual patients during 
trial conduct. The access to the code will only  be given to authorised P harmacovigilance
representatives and not be shared further. 
4.1.6 Packaging, labelling , and re -supply
The investigational products will be provided by [CONTACT_23292] a designated CRO . They  will be
packaged and labelled in accordance with the principles of Good Manufacturing Practice
(GMP ).Re-supply  to thesites will be managed via an I RT s ystem, which will also monitor 
expi[INVESTIGATOR_676967] t he site s.
For details of packaging and the description of the label, refer to the ISF.
4.1.[ADDRESS_915781] be stored in a refrigerator at a 
controlled temperature (2°C to 8°C [36°F to 46°F]) and must not be frozen. A temperature 
log will be kept at the trial site and will be completed (with a minimum and maximum 
reading) on e ach business da y. Syringes will be kept in the irouter carton in order to protect 
from light. Detailed storage conditions will be described on the trial medication labels.
Patients self -injecting at home will be instructed on the correct storage of the trial medication
at home and will be required to document storage conditions in the patient diary . 
If the storage conditions are found to be outside the specified range, the local clinical monitor 
(as provided in the list of contacts) must be contact[CONTACT_676984] .
4.1.8 Drug accountability
The designated person at each site will receive the investigational drugs delivered b y the 
sponsor when the following requirements are fulfilled:
Approval of the trial protoco l by [CONTACT_4707] (IRB)/ Independent 
Ethics Committee (I EC),
Availability  of a signed and dated clinical trial contract between the sponsor and the 
Principal I nvestigator ,
Approval/notification of the regulatory  authority , e.g., competent authorit y(CA) ,
Availability  of the curri culum vitae of the Principal Investigator ,
Availability  of a signed and dated CTP,
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 32of 84
Proprietary confidential information © [ADDRESS_915782]-03(13.0)/Saved on: 05 Aug 2015Availability  of the proof of a medical license for the Principal Investigator ,
Availability  of Form [ADDRESS_915783]’s delivery  to the trial site, the 
inventory  at the site, the administration to each patient, and dispos al of unused products. 
Unused trial medication will be destroy ed in accordance with local requirements and the 
records w ill be maintained.
These records will include dates, quantities, batch /serial numbers, expi[INVESTIGATOR_4061]  (‘use by ’) dates, 
and the unique code numbers assigned to the investigational pr oduct and trial patients. The 
designated person will maintain records that doc ument adequatel ythat the patients were 
provided the doses specified by  [CONTACT_676985] . At the time of disposal of unused products , the designated unblinded 
person must verify  that all unused or partiall y used drug supplies have been returned b y the 
clinical trial patient and that no remaining supplies are in the Investigator ’s possession.
OTHER TREATMENTS, EM ERGENCY PROCEDURES, 4.[ADDRESS_915784] refer them for appropriate ongoing care according to local 
guidelines and daily  practice, respectively .
4.2.2
Restrictions
Restrictions on prior and concomitant medications during the course of t he trial are described 
in Table 4.2.2 : 1.
Patients must be instructed not to take an y new medications or to change the dose regimen of 
any existing medication (including over -the-counter products, herbal medications ,and 
complementary  therapi[INVESTIGATOR_014]) without first consulting the investigator. All changes must be noted 
in the concomitant medication section of the eCRF.
Other medication that is considered necessary  for the patient’s safety  (e.g., as a result of an 
AE) may  be given at the investigator’s discretion. Investigators are encouraged to adhere to 
the restrictions listed in Table 4.2.2 : 1. 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 33of 84
Proprietary confidential information © [ADDRESS_915785]-03(13.0)/Saved on: 05 Aug 2015Any concomitant medications will be recorded in the appropriate sections of the eCRF.
Table 4.2.2 : 1 Prior and concomitant treatments
Treatm ent Restriction
Biologic agents (e.g., TNF 
antagonists, anti -IL12/23 and 
anti-IL17)Prior treatment with more than [ADDRESS_915786] 6 months of screening will be permitted .
Cyclophosphamide Cyclophosphamide will not be permitted w ithin 6 months prior to Day 1 and 
for the duration of the study.
Topi[INVESTIGATOR_676968] t applied on psoriatic lesions/scalp/nails will not be 
permitted within 2 weeks prior to Day 1 and for the duration of the study. 
Topi[INVESTIGATOR_676969] 2 weeks prior to Day 1 and for the duration of the study . Topi[INVESTIGATOR_676970] (WHO group VI/ VII) are permitted during the 
study except within 24 hours before study visits.
Other topi[INVESTIGATOR_676971]/scalp/nails that is likely to 
impact signs and symptoms of psoriasis (e.g. , vitamin D analogues, 
pi[INVESTIGATOR_031], retinoids, salicyl vaseline, salicylic acid, lactic acid, tacrolimus, 
tar, urea, hydroxy or fruit acids will not be permitted within 2 weeks of Day 1 
and for the dur ation of the study. However, use of emollients (moisturizing 
treatments) will be permitted during the study duration except w ithin the 24 -
hour period immediately prior to each clinic visit.
UVB , UVA or PUVA 
treatment
(photo [chemo] therapy)Treatment with UVB or UVA (w ithout psoralen) will not be permitted within 2 
weeks prior to Day 1 and for the duration of the trial. PUVA treatment will not 
be permitted within 4 w eeks prior to randomization. 
Traditional synthetic agents Systemic treatment with traditional synthetic agents (e.g., methotrexate, 
sulphasalazine, azathioprine, retinoids , fumarates ) will not be permitted w ithin 
4 weeks prior to Day 1 and for the duration of the study. 
Nutraceutical treatments Nutraceuticals intended for the treatment of psoriasis will not be permitted 
within 4 weeks prior to Day 1 and for the duration of this study.
Other systemic or locally 
acting medicationsTreatment with any other systemic or locally acting medications which might 
counter or influence the objective of the study (e.g., nonsteroidal 
anti-inflammatory drug [NSAID ], antihistamine) is only permitted f or 
occasional (single dose) use; medications k nown to potentially provoke or 
aggravate psoriasis (e.g., lithium, beta -blockers or antimalarial drugs), will 
only be permitted if the doses of such agents are stable within 4 w eeks prior to 
Day 1 and are planned to remain so for the duration of this study .
Live/attenuated vaccine Not permitted w ithin [ADDRESS_915787] dose of trial drug .
Any drug/therapy that has not 
received regulatory approval 
for any indicationNot permitted w ithin 12 w eeks or a minimum of five half -lives, whichever is 
longer, prior to Day 1.
IV Gamma Globulin Not permitted w ithin 6 months of the Screening Visit.
Intravenous, intramuscular, 
intra-articular or parenteral
corticosteroidsNot permitted w ithin 6 weeks prior to Day 1 andthroughout the trial.
Oral corticosteroids Not permitted w ithin 4 weeks prior to Day 1 andthroughout the trial.
Prosorba®Column Not permitted w ithin 6 months of the Screening Visit.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 34of 84
Proprietary confidential information © [ADDRESS_915788]-03(13.0)/Saved on: [ADDRESS_915789] 8 w eeks prior to Day 1 andthroughout the trial .
Abbreviations: IL=interleukin; NSAID=nonsteroidal anti -inflammatory drug; TNF=tumor necrosis factor; UVA=ultraviolet 
A light; UVB=ultraviolet B light. 
Restrictions on diet and life sty le [IP_ADDRESS]
Moisturizers/emollients cont aining retinoids and the use of tanning beds are not allowed 
during the stud y.
Male subjects with female partner(s) of child- bearing potential must agree to use a medicall y
acceptable method of contraception during the trial and for [ADDRESS_915790] dose of 
trialdrug.
Restrictions regarding women of childbearing potential [IP_ADDRESS]
A serum beta-human Chorionic Gonadotropin (β-hCG )test will be performed at Screening in 
women of childbearing potential. A local urine pregnancy  test will be then performed as 
indicated in the Flow Chart . Any woman with a confirmed positive pregnancy test during 
screening is not eligible for the trial. A positive urine pregnancy  test during the treatment 
periods of the stud y requires immediate interruption of study treatment until serum β -hCG is 
performed and found to be negative. If the serum β- hCG test is positive, the patient must be 
discontinued from the trial.
Female patients of childbearing potential must use the contraception methods described in
Section 3.3.2 and the patient information. Acceptable methods of birth control include, for 
example, birth control pi[INVESTIGATOR_3353], intrauterine devices (IUDs), surgical sterilization, vasectomized 
partner and double barrier method (for example male condom in combination with female 
diaphragm/cervical cap plus spermicidal foam/gel/film/cream/suppository ).
*Women of childbearing potential are defined as:
having experienced menarche and 
not postmenopausal (12 months with no menses without an alternative medical cause) and 
not permanentl y sterilized (e.g., tubal occlusion, hysterectom y, bilateral oophorectom y or 
bilateral salpi[INVESTIGATOR_8820] y).
Restrictions regarding male participants of reprod uctive potential [IP_ADDRESS]
Male participants with female partner(s) of child -bearing potential must agree to use a 
medically acceptable method of contraception during the trial and for [ADDRESS_915791] additionally  use 1 of the
following methods if they are not pregnant: hormonal contraception, intrauterine device
(IUD), diaphragm, or cervical cap. If their partner is pregnant, males must agree to use a 
condom and no additional method of contr aception is required for the pregnant partner. Male 
subjects must also agree to not donate sperm during the trialand for a period of [ADDRESS_915792] dose of trialdrug
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 35of 84
Proprietary confidential information © [ADDRESS_915793]-03(13.0)/Saved on: 05 Aug 2015TREATMENT COMPLIANCE 4.3
Compliance on study  visit day s (Weeks 0 and 1) will be a ssured b y the observation of trial 
medication administration by [CONTACT_676986]. 
Between designated site visits (Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23), the patient 
may self-inject the trial medication at home. Patients will be instructed to notify  the site if 
they miss a dose or receive a partial dose so the Investigator can determine a ny necessary  
follow -up. For all trial medication injections, patients will be asked to complete a patient 
diary  documenting the date and time of the injections and problems encountered with dosing
(missed or incomplete injections should be recorded as well).
All used and unused syringes must be returned to the site at each visit.
Patients showing poor compliance as assessed b y missing their allocated day s for trial 
medication administration must be counseled on the importance of good compliance to the 
trial dosing regimen. 
Subjects who are non -compliant (for instance, who 
do not appear for scheduled visits or 
violate trial restrictions) may  be removed from the trial by [CONTACT_676987]’s representative, and the eCRF will be completed accordingly .
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 36of 84
Proprietary confidential information © [ADDRESS_915794]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. VARIABLES AND THEIR ASSESSMENT
Please refer to the Flow Chart for the Schedule of Assessments for the trial. 
The trial endpoints are listed in Section 5.1below. Efficacy  assessments are described in 
more detail in Section 5.2,safet y assessments in Section 5.3, and PK sample collection in 
Section 5.4. 
TRIAL ENDPOINTS 5.1
5.1.1 Primary Endpoint
The primary  endpoint is:
Proportion of patients with a 75% reduction in Psoriasis Area and Severity I ndex (PASI
75)response at Week 16
5.1.2 Secondary Endpoint s
Secondary  endpoints are:
Efficacy
Proportion of patients with a PASI 75 response at Week 24
Mean percentage improvement in PASI  at Week 16 
Proportion of patients with a sPGA ≤ 1 (clear or almost clear) at Week 16 
Proportion of patients achieving a Dermatology  Life Quality  Index (DLQI) of 0 or 1 at 
Week 16 
Safety
Proportion of patients with drug- related AEs

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 37of 84
Proprietary confidential information © [ADDRESS_915795]-03(13.0)/Saved on: 05 Aug 2015Safety
Proportion of patients with AEs, SAEs and AEs of Special Interest (AESIs) (e.g., serious 
infections and hy persensitivity  reactions) ;
 
 
 
ASSESSMENT OF EFFICA CY 5.2
The following assessments will be made at the time points indicated in the Flow Chart for the 
purpose of calculating the PASI , sPGA, and DLQI scores.
5.2.1 PASI
The PASI  is an established measure of clinical efficacy  for psoriasis m edications. ( R96- 3541)
The PASI  is a tool which provides a numeric scoring for patients overall psoriasis disease 
state, ranging from 0 to 72. I t is a linear combination of percent of surface area of skin that is 
affected and th e severity  of ery thema, induration , and desquamation over four body  regions. 
The endpoints used are based on the percent reduction from B aseline, generally  summarized 
as a dichotomous outcome based on achieving over an X% reduction (or PASI X), where X is
50, 75, 90, and 100.
To calculate the PASI , the 4main body  areas are assessed: head (h), trunk (t), upper 
extremities (u) and lower extremities (l). These correspond to 10, 30, 20, and 40% of the 
total body  area ,respectively .
The area of psoriatic in volvement of these four areas (Ah, At, Au, and Al) is given a 
numerical value: 0 = no involvement, 1 = < 10%, 2 = 10 to < 30%, 3 = 30 to < 50%, 4 = 50 to 
<70%, 5 = 70 to < 90%, and 6 = 90 to 100% involvement.( Figure 10.2: 2)

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 38of 84
Proprietary confidential information © [ADDRESS_915796]-03(13.0)/Saved on: 05 Aug 2015The signs of severity, erythema (E), in duration (I) and desquamation (D) of lesions are 
assessed using a numeric scale [ADDRESS_915797] possible involvement; scores are made independently  for each of the areas, h, 
t, u,and l and represents a composite score for each area. An illustration of judging erythema 
follows: 0 = no erythema, 1 = slight ery thema, 2 = moderate ery thema, 3 = severe erythema, 
and 4 = very severe erythema.
The PASI  score is cal culated according to the following formula:
PASI  = 0.1( Eh+Ih+Dh)Ah + 0.3(Et+It+Dt)At + 0.2(Eu+Iu+Du)Au + 0.4(El+I l+Dl)Al
(Appendix 10.2, Figure 10.2: 4)
5.2.2 Static Physician’s Global Assessment
The sPGA is a 5- point score ranging from 0 to 4, based on the ph ysician’s assessment of the 
average thickness, ery thema, and scaling of all psoriatic lesions. The assessment is 
considered “static” , which refers to the subject’s disease state at the time of the assessments, 
without comparison to any of the subject’s previous disease states (dynamic) , whether at 
Baseline or at a previous visit (Appendix 10.2, Figure 10.2: 1).
A lower score indicates less body  coverage, with [ADDRESS_915798] clear. 
Erythema  (0)   Normal ( Post-inflammatory  hyperpi[INVESTIGATOR_417803]
(1)   Pi[INVESTIGATOR_108997]
(2)   Light red coloration of lesions
(3)   Dull to bright red coloration of lesions
(4)   Bright to deep red coloration of lesions
Induration (0)   None
(1)  Just detectable 
(2)  Mild thickening
(3)  Clearly  distinguishable to moderate thickening
(4)  Severe thickening with hard edges
Scaling (0)   No scaling
(1)  Minimal focal scaling
(2)  Predominately  fine scaling
(3)  Moderate scaling
(4)  Severe /coarse scaling covering almost all or all les ions
Scoring:
Clear 0 = [ADDRESS_915799] clear 1 = mean > 0, <1.5
Mild 2 = mean >= 1.5, < 2.5
Moderate 3 = mean >= 2.5, < 3.5
Severe 4 = mean >= 3.5
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 39of 84
Proprietary confidential information © [ADDRESS_915800]-03(13.0)/Saved on: [ADDRESS_915801] -administered, ten -question, quality  of life questionnaire that covers 
6domains including s ymptoms and feelings, daily activities, leisure, work and school, 
personal relationships and treatment (R05-2548). TheDLQI has a one -week recall period. 
Item scores range from 0 (not relevant) and 1 (not at all) to 3 (very  much). Question 7 is a 
“yes”/ “no” question where “y es” is scored as 3.
The DLQI will be self -administered by  [CONTACT_676988] t he Flow C hart.
The DLQI will be anal yzed under 6headings as follows ( R05-2548 ):
Domain Question Number Score
Symptoms and feelings Questions 1 and 2 Score maximum 6
Daily  activities Questions 3 and 4 Score maximum 6
Leisure Questions 5 and 6 Score maximum 6
Work and school Question 7 Score maximum 3
Personal relationships Questions 8 and 9 Score maximum 6
Treatment Question 10 Score maximum 3
DLQI total score is calculated by  [CONTACT_417833] a range of 
0 to 30 where 0- 1 = no effect on subject’s life, 2 -5 = small effect , 6-10 = moderate effect, 
11-20 = very  large effect, and 21 -30 = extremely  large effect on subject’s life. The high er the 
score, the more the quality  of life is impaired. If the answer to 1question in a domain is 
missing, that domain is treated as missing. 
If 2 or more questions are left unanswered 
(missing), DLQI total score is treated as missing. A 5-point change fr om B aseline is 
considered a clinicall y important difference (Figure 10.2: 3).
 
 
 
 
 
 
 
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 40of 84
Proprietary confidential information © [ADDRESS_915802]-03(13.0)/Saved on: [ADDRESS_915803] 
information, informed consent, demographics including height and bod y weight, smoking 
and alcohol history , relevant medical history  and concomitant therap y, review of inclusion 
and exclusion cri teria, review of vital signs (blood pressure, pulse ra te, temperature ), 12-lead 
ECG, laboratory  tests (including virus screening , IGRA/[COMPANY_003] test [where applicable], 
pregnancy  test for females) , and a ph ysical examination. 
On all other visits, it will include review of vital signs, 12-lead ECG, laboratory  tests 
(including IGRA at SFU ), pregnancy  test for females and a ph ysical examination. 
Adverse events and concomitant therapi[INVESTIGATOR_676972].
Whenever possible, the same person should perform the phy sical examination throughout the 
trial (i.e., for all patients at each trial site).
5.3.1 Physical examination
A phy sical examination will be performed at the visits indicated in the Flow Chart .
The phy sical examination will include assessment of general appearance, skin, head, neck, 
throat, ly mph nodes, cardiovascular andneurological systems ,thyroidgland, musculoskeletal
system /limbs , respi[INVESTIGATOR_656809].
 
linically  relevant abnormal findings will be rep orted as B aseline 
conditions or AEs.
5.3.[ADDRESS_915804] 
while the patient is in a sitting position. The patient’s body  temperature will also be recorded.
The method of measuring bod y temperature (oral/aural) should be consistent a t a specific trial 
site.
The investigator must assess all vital signs findings and if the investigator finds any  clinically  
relevant abnormalities, these must be reported as AEs / SAEs as appropriate.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 41of 84
Proprietary confidential information © [ADDRESS_915805]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].3.3 S afety laboratory parameters
The laboratory  tests listed in Table 5.3.3: 1 will be a nalyzed by a central laboratory . The 
central laboratory  provider will also provide the materials for blood sampling. Instructions for 
the labeling, storage ,and shipment of the samples as well as details of all blood variable units 
and reference ranges can be found in the Laboratory Manual.
Pregnancy  testing will be performed by  a cen tral laboratory  using serum at S creening and
local laboratory  using urine at all applicable visits thereafter. 
Fortime points of laboratory  sampling, see theFlow Chart .
Laboratory  results (i.e. ,all safety  laboratory  and clinical laboratory  data relevant for current 
clinical practice) of the patients will be available to the respective investigator (via laboratory  
reports) and to the sponsor (via the central laboratory  website) and selected abnormal 
laboratory  alerts will be flagged to the site an d sent to sponsor in real time.
The investigator must assess all laboratory  results, evaluate any  change in laboratory  values, 
and review all clinical laboratory  tests for potential clinical significance at all time points 
throughout the trial. The investigator should endeavor to provide a reason for all out -of-range 
results deemed not clinical ly significant. If the investigator determines a laboratory  
abnormality  to be clinically  significant, it will be co nsidered an AE /SAE (see 
Section [IP_ADDRESS]); however, if the laboratory  value abnormality  is consistent with a current 
diagnosis, it will be documented accordingly .
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 42of 84
Proprietary confidential information © [ADDRESS_915806]-03(13.0)/Saved on: 05 Aug 2015Table 5.3.3: [ADDRESS_915807]
Hb
RBC count / erythrocytes
White blood cells / leukocytes
Platelet count / throm bocy tes
Diff. Automatic Neutrophils (relative count)
Lymphocytes (relative count)
Diff. Manual (if Diff Automatic is abnormal) Neutrophils, bands ( stabs)
Neutrophils, polymorphonuclear
Lymphocytes
Enzymes AST (GOT)
ALT (GPT)
Creatine Kinase
CK-MB, only if CK is elevated
Gamma -Glutamyl Transferase ( GGT)
Electrolytes Calcium
Sodium
Potassium
Chloride
Substrates Glucose
Creatinine
Bilirubin total
Bilirubin direct (if total is elevated)
Bilirubin indirect (if total is elevated)
Total protein
Albumin
Cholesterol, total
Urine Pregnancy test (only for female patients of 
childbearing potential) at randomization and 
continued as indicated in the Flow  Chart (including 
EoT and E nd of Observational Period Visit)Human Chorionic Gonadotropin in the urine
Serum Pregnancy test (only for female patients of 
childbearing potential) at screening and if urine 
pregnancy test is positive) Human Serum Chorionic Gonadotropin 
Urinalysis (dipstick) Urine Protein
Urine Glucose
Urine RBC / erythrocytes
Screening for infections (only at screening) HBsAg (qualitative)
Hepatitis C antibodies (qualitative)
HIV-1, and HIV- 2 antibody (qualitative, where 
mandated by [CONTACT_676989])
Screening for infections (only at screening and Eo T 
Visit)TB test ( IGRA :QuantiFERON®Gold 
assay /T-SPOT®.TB)
([COMPANY_003] skin test at the discretion of the investigator 
where clinically indicated )1
Abbreviations: ALT= alanine aminotransferase ; AST= aspartate aminotransferase ; CK -MB= Creatine Kinase -MB ; EoT=End 
of Treatment; Gamma -GGT =Glutamyl Transferase; GOT= Glutamic -Oxaloacetic Transaminase ; 
GPT=Glutamic -Pyruvic Transaminase ; Hb=hemoglobin; Hct= hematocrit ;HIV=h uman immunodeficiency virus ; 
IGRA= interferon gamma-release assay ; [COMPANY_003]= purified protein derivative ;TB=tuberculosis. 
1There is the trial site option to perform a [COMPANY_003] skin test, although this will not be provided or performed at Central La b.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 43of 84
Proprietary confidential information © [ADDRESS_915808]-03(13.0)/Saved on: [ADDRESS_915809] be stored in the patients’ medical record as 
source data. A ph ysician familiar with interpretation of ECG will evaluate the ECG from a 
clinical perspective and the result (whether the ECG result is normal, abnormal not clinically  
relevant or abnormal clinically  relevant) will be recorded in the appropriate section of the 
eCRF.
5.3.5 O ther safety parameters
Local tolerability [IP_ADDRESS]
The assessment of i njection site reactions willbe done by [CONTACT_73486]/designee
according to “swelling”, “ hardening”, “heat”, “redness ”, “pain”, “itching”, “bruising”, or 
“other sy mptoms”. If any injection site reaction s
are observed, these findings should also be 
reported on the AE eCRF p age.
5.3.6 Assessment of adverse events
Definitions of AEs [IP_ADDRESS]
Adverse event
An AEis defined as a ny untoward medical occurrence in a patient or clinical investigation 
subject administered a medicinal product and which does not necessaril y have to have a 
causal re lationship with this treatment.
An AE can therefore be any  unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
Adverse reaction
An adverse reaction is defined as a response to a medicinal product which is noxious and 
unintended. Response in this context means that a causal relationship between a medicinal 
product and an adverse event is at least a reasonable possibility . Adverse reactions may  arise 
from use of the product within or outside the terms of the marketing authori zation or from 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 44of 84
Proprietary confidential information © [ADDRESS_915810]-03(13.0)/Saved on: 05 Aug 2015occupational exposure. Conditions of use outside the marketing authorization include 
off-label use, overdose, misuse, abuse, and medication errors.
Serious adverse event
AnSAE is defined as any AE which:
results in death,
is life -threatening, which refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might have 
caused death if more severe.
requires inpatient hospi[INVESTIGATOR_478648] 
prolongation of existing hospi[INVESTIGATOR_18543],
results in persistent or signif icant disability  or incapacity ,or
is a c ongenital anomal y /birth defect,
or
is deemed serious for any other reason if it is an important medical event when based 
on medical judgment which may  jeopardise the patient and may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definitions.
Medical and scientific judgement should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_82340] m ight jeopardi ze the 
patient or might require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm, blood dy scrasias or convulsions that do not result in hospi[INVESTIGATOR_676973]. Any  suspected transmission via a medicinal product of 
an infectious agent is also considered a serious adverse reaction.
AEs considered “Always Serious”
Cancers of new histology and exacerbations of existing cancer must be reported as a serious 
event regardless of the duration between discontinuation of the drug and the occurrence of the 
cancer .
In accordance with the European Medicines Agency initiative on Important Medical Events, 
BIhas set up a list of further AEs, which b y their nature, can alway s be considered to be 
“serious” even though they  may  not have met the criteria of an SAE cited above.
A cop y of the latest list of “Always Serious AEs” can be found in the ISFand eCRF . These 
events should alway s be reported as SAEs as described above .
Adverse events of special interest 
The term AESI relates to any  specific AE that has been identified at the project level as being 
of particular concern for prospective safet y monitoring and safet y assessment within this trial, 
e.g.,the potential for AEs based on knowledge from other compounds in the same class. 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 45of 84
Proprietary confidential information © [ADDRESS_915811]-03(13.0)/Saved on: 05 Aug 2015AESI  need to be reported to the sponsor ’s/sponsor designee Pharmacovigilance Department 
within the same timeframe that applies t o SAE, please see above .
The following are considered as AESIs:
1.Hepatic injury
A hepatic injury  is defined by  [CONTACT_15624]: 
an elevation of AST and/or ALT ≥ 3-fold ULN combined with an elevation of total 
bilirubin ≥
2-fold UL N measured in the same blood draw sample, and/or
marked peak aminotransferase (ALT, and/or AST) elevations ≥
10-fold ULN
These lab findings constitute a hepatic injury  alert and the patient s showing these lab 
abnormalities need to be followed up according to the “DILI checklist” provided in the I SF.
In case of clinical s ymptoms of hepatic injury  (icterus, unexplained encephalopathy , 
unexplained coagulopathy , right upper quadrant abdominal p
ain, etc.) without lab results 
(ALT, AST, total bilirubin) available, the Investigator should make sure these parameters are 
analyzed, if necessary  in an unscheduled blood test. Should the results meet the criteria of 
hepatic injury  alert, the procedures described in the DILI checklist should be followed .
2.Anaph ylactic reactions
3.Serious infection (defined as infections requiring IV antibi otics or meeting the regulatory  
definition of a SAE)
4.Hypersensitivity  reactions
Intensity of AEs
The intensity  of the AE should be judged based on the following:
Mild: Awareness of sign(s) or sy mptom(s) that is/are easily  tolerated
Moderate: Sufficient discomfort to cause interference with usual activity
Severe: Incapacitating or causing inability  to work or to perform usual activities
Causal relationship of AEs
The definition of an adverse reaction implies at least a reasonable possibility of a causal 
relationship between a suspected medicinal product and an AE. An adverse reaction, in 
contrast to an AE, is characterised b y the fact that a causal relationship between a medicinal 
product and an occurrence is suspected. 
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de -challenge or re -challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history . 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 46of 84
Proprietary confidential information © [ADDRESS_915812]-03(13.0)/Saved on: [ADDRESS_915813] that there is a reasonable possibility  of a causal relationship 
could be :
The event is consistent with the known pharmacology of the drug 
The event is known to be caused b y or attributed to the drug class.
A plausible time to onset of the event relative to the time of drug exposure.
Evidence that the event is reproducible when the drug is re -introduced
No medicall y sound alternative aetiologies that could explain the event (e.g. ,pre-existing
or concomitant diseases, or co -medications).
The event is t ypi[INVESTIGATOR_1306] y drug -related and infrequent in the general population not exposed 
to drugs (e.g., Stevens -Johnson sy ndrome).
An indication of dose -response (i.e., greater effect size if the dose is increased, smaller 
effect size if dose is diminished).
Arguments that may  suggest that there is no reasonable possibility  of a causal relations hip 
could be:
No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g.,pre-treatment cases, diagnosis of cancer or chronic disease within days /weeks of 
drug administration; an allergic reaction weeks after disconti nuation of the drug 
concerned) .
Continuation of the event despi[INVESTIGATOR_15576], taking into account 
the pharmacological properties of the compound (e.g. ,after 5 half -lives).
Of note, this criterion may not be applicable to events whose time course is prolonged 
despi[INVESTIGATOR_15577].
Additional arguments amongst those stated before, like alternative explanation (e.g. ,
situations where other drugs or underl ying diseases appear to provide a more likely  
explanation for the o bserved event than the drug concerned).
Disappearance of the event even though the study  drug treatment continues or remains 
unchanged.
Adverse event collection and reporting [IP_ADDRESS]
AE Collection
The Investigator shall maintain and keep detailed records of all AEs in their patient files.
The following must be collected and documented on the appropriate eCRF(s) by  [CONTACT_3786]:
From signing the informed consent onwards through the Residual Effect Period (REP , [ADDRESS_915814] stud y drug administration ), until individual patient’s end of trial: 
oall AEs (serious and non -serious) and all AESIs .
However, if an individual patient discontinues trial medication prematurel y but stay s 
in the trial (i.e.,iffurther visits including telephone visits or vital status assessments
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 47of 84
Proprietary confidential information © [ADDRESS_915815]-03(13.0)/Saved on: 05 Aug 2015are planned )from then on and until the individual patient’s end of the trial the 
Investigator must report related SAEs and related AESI s.
After the individual patient’s end of trial:
othe Investigator does not need to activel y monitor the patient for AEs but 
should only  report relevant SAEs and relevant AESI s of which the 
Investigator may become aware of.
The residual effect period ( REP)is defined as [ADDRESS_915816] report SAEs, AESI s, and non -serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately  (within 24 hours ) to the 
sponsor’s /sponsor’s designee unique entry  point (contact [CONTACT_15626]). 
The same timeline applies if follow-up information becomes available. In specific occasions,
the Investigator could inform the s ponsor /sponsor designee upfront via telephone. This does 
no
t replace the requirement to complete and fax the BI SAE form.
With receipt of an y further information to these events, a follow -up SAE form has to be 
provided. For follow -up information the same rules and timeline apply  as for initial 
information.
Information required
For each AE, the Investigator should provide the information requested on the appropriate 
eCRF pages and the BI SAE form. The Investigator should determine the causal relationship 
to the trial medication and any possible interactions b etween the investigational drug s.
The following should also be recorded as an (S)AE in the e CRF and SAE form (if 
applicable):

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 48of 84
Proprietary confidential information © [ADDRESS_915817]-03(13.0)/Saved on: 05 Aug 2015Worsening of the underly ing disease that cannot be explained with the natural fluctuation 
of disease severit y or of other pre -existing conditions
Changes in vital signs, ECG, phy sical examination and laboratory  test results, if they  are 
judged clinically  relevant by  [CONTACT_737].
If such abnormalities already  pre-exist prior to trial inclusion they  will be considered as 
Baseline conditions.
All (S)AEs, including those persisting after individual patient’s end of trial ,must be followed 
up until they  have resolved, have been sufficiently  character ized, or no further information 
can be obtained.
Pregnancy
In rare case s pregnancy  mayoccur in a clinical trial. Once a patient has been enrolled into
this clinical trial and has taken trial medication, the Investigator must report immediately  
(within 24 hours) a potential drug exposure during pregnancy to the sponsor ’s/sponsor 
designee unique entry  point (contact [CONTACT_15626]). The Pregnancy 
Monitoring Form for Clinical Trials (Part A) should be used.
The outcome of the pregnancy  associated with the drug exposure during pregnancy  must be 
followed up and reported to the s ponsor’s /sponsor’s designee unique entry  point on the 
Pregnancy  Monitoring Form for Clinical Trials (Part B).
The I SF will contain the Pregnancy  Monitoring Form for Clinical Trials (Part A and B).
As pregnancy  itself is not to be 
reported as an AE, in the absence of an accompany ing SAE 
and/or AESI, onl y the Pregnancy Monitoring Form for Clinical Trials and not the SAE form 
is to be completed. If there is an SAE and/or AESI associated with the pregnancy  an SAE 
form must be completed in addition.
 
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 49of 84
Proprietary confidential information © [ADDRESS_915818]-03(13.0)/Saved on: 05 Aug 2015

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 50of 84
Proprietary confidential information © [ADDRESS_915819]-03(13.0)/Saved on: 05 Aug 2015

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 51of 84
Proprietary confidential information © [ADDRESS_915820]-03(13.0)/Saved on: 05 Aug 2015

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 52of 84
Proprietary confidential information © [ADDRESS_915821]-03(13.0)/Saved on: [ADDRESS_915822] .
 
Therefore, the appropriateness of all measurements applied in this trial is assured .
Information about race should be obtained from all study  participants as allowed by  [CONTACT_13125]. This is because the prevalence and characteristics of psoriasis differ widely  
between patients of different racial origin. It will thus be worthwhile to assess if patients of 
different race will respond differentl y to the stud y treatment.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 53of 84
Proprietary confidential information © [ADDRESS_915823]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. INVESTIGATIONAL PLAN
VISIT SCHEDULE 6.1
A schedule of assessments is provided in the Flow Chart .
Each visit date (with its window) is to be counted from Day  1(randomization). If any visit 
has to be rescheduled, the 2-week regimen for trial medication administration should resume 
from the time the last dose was administered. Additional visits for the purpose of re -testing of 
laboratory  paramet ers or AE monitoring may  be included as deemed necessary  by [CONTACT_1275].
A visit window of -1 / + 2 day s is permitted for Visit 2 (Day  1)
A visit window of ± 2 days is permitted from Visit 3 up to Visit 7
A visit window of ± [ADDRESS_915824] be drawn prior to trial medication injection.
The questionnaire will be completed at the site by  [CONTACT_102] (DLQI) before any  
investigations or discussions about their disease with the clinic staff and may onl y be 
recorded b y a trial nurse/investigator on behalf of the patient if the patient has difficulty 
writing during the visit or is unable to read. T his must be documented clearly  in the patient 
notes.
Also the s cales areto be completed by  [CONTACT_147568] (PASI sPGA, 
All questionnaires and scales are detailed in Appendix 10
.
The total estimated volume of blood that will be drawn from each patient during the course of 
the trial is shown in Table 6.1: 1 .
Table 6.1: 1 Estimated blood sample volumes per pati ent
Param eter Sample volume (mL) Number of samples Total volum e (mL)
Laboratory tests (including serum 
chemistry, serum pregnancy test)[ADDRESS_915825] 3 2 6
Approxim ate total 82
Abbreviations: ADA= anti-drug antibodies; nAb=neutralizing ADA ; TB= tuberculosis .
Additional samples may be required if medically indicated, e.g., at unscheduled visits to follow safety findings.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 54of 84
Proprietary confidential information © [ADDRESS_915826]-03(13.0)/Saved on: 05 Aug 2015DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS 6.2
Study  procedures to be performed at each visit are listed in the Flow Chart and the respective 
protocol sections. Refer to Section 5for explanations of procedures. Additional details on 
procedures at selected visits are provided below. 
6.2.1 Screening and run -in period(s)
Screening Period
Once the patient has provided informed consent (before any  trial-specific proced ures or 
assessments are performed), meets the inclusion criteria and does not meet the exclusion 
criteria (see Section 3.3), t he following will be performed/collected:
Demographic information (including gender, date of birth, ethnicity ,and race), and 
medical and surgical history  (including psoriasis history  and history  of opportunistic 
infection)
Infection screen (TB, HBsAg, anti-hepatitis B core antibodies [ anti-HBc] , anti- HCV ,and 
HIV test, per the investigator’s discretion)
Chest X -ray, unless taken within the previous 12 weeks 
TB test 
Serum pregnancy  test for women of child -bearing potential
Physical examination, including height (cm) and weight (kg) 
Vital signs (blood pressure, pulse rate, and bod y temperature)
Laboratory  testing (serum chemistry , hematology ,and urinal ysis)
12-lead ECG 
Previous and conc omitant therapy  
Assessment of AEs 
Efficacy  assessments: PASI , sPGA, DLQI, 
Once patients have completed screening, have met all the inclusion criteria and none of the
exclusion criteria, randomization can occur through a registration call through a standard 
randomization visit call, using the IRTsystem. The Day  1 randomization or registration call 
will depend on the trial site procedure. Patients will be randomized t o each treatment in a 1:1 
ratio (BI 695501: US-licensed Humira) according to the s
tratification factors. The 
registration call can be made within [ADDRESS_915827] administration of trial 
medication. Eligible patients w ill then be confirmed to the randomization scheme on Day  1 
(or when the drug is at site), according to their randomization. Eligible patients will be 
randomized in blocks to double -blind treatment at Day  1 according to the randomization. 
Patients will be randomly assigned in a blinded fashion to BI 695501 or US -licensed Humira .

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 55of 84
Proprietary confidential information © [ADDRESS_915828]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].2.2 Treatment period
Baseline, Visit 2 (Day  1)
For the duration of the trial, BI 695501 / US- licensed Humira will be administered b y a
suitably  qualified, designated trial personnel, either at the site or at the patient’s home. 
Eligible patients will be randomized  and will receive their first administration of trial 
medication on Day  1.
The following will also be performed/ collected:
Urine pregnancy  test for women of child- bearing potential
Physical examination (see Section 5.3.1)
Vital signs 
Laboratory  testing (serum chemistry , hematology and urinal ysis)
Previous and concomitant therap y (see Section 4.2 )
Assessment of AEs (see Section 5.3.6)
Previous and concomitant therap y 
Efficacy  assessments: PASI , sPGA, DLQI, (see Section 5.2)

Contact I RT
The first 
injection of trial medication
Visit 3
The following will be performed/collected:
Assessment of AEs and concomitant therap y
Contact I RT, training and administer trial medication
Visit s 4to [ADDRESS_915829] the dates and times of trial medication dosing; 
problems encountered with dosing; the 
occurrence of an y AEs; the use of concomitant therapi[INVESTIGATOR_014]; a nd the prefilled sy ringe storage 
conditions on the provided diary  cards between the site visits. The patient will be instructed 
to contact [CONTACT_676990].
The followi ng will be performed/collected:
Urine pregnancy  test for women of child- bearing potential (Visit s 5, 7, 9)

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 56of 84
Proprietary confidential information © [ADDRESS_915830]-03(13.0)/Saved on: 05 Aug 2015Physical examination (Visits 5, 7, 9)
Vital signs (blood pressure, pulse rate, and bod y temperature; see Section 5.3.2) (Visits 5,
7,
9)
Laboratory  testing (serum chemistry , hematology and urinal ysis; see Section 5.3.3) 
(Visits 5, 7, 9)
12-lead ECG (Visit s 5, 7, 9) (
Assessment of AEs and concomitant therap y
Review of the patient diary card entries
Efficacy  assessments: PASI , sPGA, DLQI; (see Section 5.2)

Contact I RT and administer trial medication (see Section 
4.1.4)
The patient will return all used and unused trial medication at each visit after Week 4 and will 
bring his /her patient diary  for review
. Prefilled sy ringes will be collected by  [CONTACT_676991] , as instructed in the I SF.
6.2.3 Follow -up Period and Trial Completion
Patients who discontinue the tri al prematurely  at any  time after Day  1 including patients with 
discontinued treatment at week 16 due to lack of efficacy  (but do not withdraw their consent) 
will, at discontinuation, have an End of Treatment (EoT) Visit equivalent to the Week 24 
assessment s (except trial medication administration). Patients who discontinue the trial will 
also 
be required to have all of the evaluations planned for Visit 10 ( Week 34) [ADDRESS_915831] administered dose of trialmedication . These patients should be registered as 
prematurel y discontinued in I RT.
The following will be performed/collected:
Urine pregnancy  test for women of child
-bearing potential
Physical examination, including weight (kg) (see Section 5.3.1)
Vital signs 
Laboratory  testing (serum chemistry , hematology ,and urinal ysis)
Previous and concomitant therap y (see Section 
4.2)
Assessment of AEs and concomitant therap y 
Review patient diary
TB test 
Unscheduled visit assessments
Patients may  attend the trial site for unscheduled visits at any  time for additional safet y 
monitoring at the discretion of the investigator. 
All abnormal values that are judged clinically  relevant by  [CONTACT_676992] a return to a medically  acceptable level is achieved. Adverse 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 57of 84
Proprietary confidential information © [ADDRESS_915832]-03(13.0)/Saved on: [ADDRESS_915833] 
been sufficiently  characteri zed.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 58of 84
Proprietary confidential information © [ADDRESS_915834]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZ E
STATISTICAL DESIGN - MODEL 7.1
This is a randomized, double -blind, parallel- arm, multiple -dose, active comparator, 
multi- center, multi -national trial .
The primary  objective of this trial is to establish equiv alence between BI 695501 and 
US-licensed Humir a in terms of efficacy  at Week 16 i n patients with active moderate to 
severe chronic plaque psoriasis.
Equivalence in efficacy between BI 695501 and US -sourced Humira will be based on a 
comparison of:
Proportion of patients with a PASI 75 response at Wee k 16 with a margin of ± 18%.
Based upon these design considerations, the trial will be anal yzedusing logistic regression, 
which will include term for baseline PASI as covariate. Details of the models are presented 
below .
NULL AND ALTERNATIVE HYPOTHESES 7.[ADDRESS_915835] can be written as follows:
H0: Difference in PASI 75 response rates at Week 16 (BI 695501 versus US-
sourced 
Humira) is less than 
-18% or more than 18%
H1: Difference in PASI 75 response rates at Week 16 (BI 695501 versus US-sourced 
Humira) is within [- 18%, 18%]
To conclude equivalence, the two-sided 
95% CI of the difference in PASI 75 response rate 
(BI 695501 –Humira) has to be fully  within the equivalence limits of ± 18%.
PLANNED ANALYSES 7.3
The primary  anal ysis set will be the Full Anal ysis Set (FAS) according to the intention to 
treat principle. For all efficacy  anal yses, the FAS consists of all randomized patients who 
received at least [ADDRESS_915836] -baseline.
A Per -Protocol Set (PPS) of patients who have followed the CT
P in all essential criteria will 
be created for sensitivity  anal yses. Patients included in the FAS who have important protocol 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 59of 84
Proprietary confidential information © [ADDRESS_915837]-03(13.0)/Saved on: [ADDRESS_915838] a distorting influence on the assessment of 
the primary  endpoint. Such i mportant protocol violations will be defined further in the TSAP 
and include:
Incorrect trial medication taken
Severe violation of treatment compliance
Severe violation of inclusion/exclusion criteria
All patients treated with at least 
1dose of trial medication will be included in the safet y 
evaluation (Safety  Anal ysis Set [SAF]).
Further details on the definition of the different analy sis sets will be provided in the Trial 
Statistical Analy sis Plan (TSAP ).
7.3.1 Primary endpoint analyses
The primary  anal yses will be performed on the FAS. Patients will be assigned to the 
treatment they  were randomized to.
The primary  anal ysis of the observed difference in PASI 75 response rates at Week 16 will be 
based on logistic regression with subsequent transformation of the estimated parameters to 
the difference in proportions. Multiple imputation ( MI) method will be used to deal with 
missing data (see Section 7.5).
The estimates from the logistic regression are on the logit scale, and the dif ference in 
proportions will be calculated as the difference between the predicted probabilities in the 
treatment groups on the original scale, with the variance calculated using the cumulative 
distribution function method of Reeve (Statistical Methods in M edical Research, forthcoming 
2016); details will be provided in the TSAP.
The statistical model can be described as follows:
(M1) Logit(response to treatment at Week 16) = treatment + Baseline PASI + random error
This model includes fixed, categorical effects of:
Treatment (BI 695501 versus US- sourced Humira)
and continuous effect of:
Baseline PASI 
The random error is assumed to be binomially  distributed.
As sensitivity  anal ysis the primary  endpoint will also be anal yzed on the PPS with non-
responder imputation (NRI ) using M1 as for the primary  anal ysis. 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 60of 84
Proprietary confidential information © [ADDRESS_915839]-03(13.0)/Saved on: 05 Aug [ZIP_CODE].3.2 Secondary endpoint analyses
Secondary  efficacy  endpoints [IP_ADDRESS]
Secondary  efficacy  endpoints: 
Proportion of patients with a PASI 75 response at Week 24
Mean percentage improvement in PASI  at Week 16
Proportion of patients with sPGA ≤ 1 at Weeks 16
Proportion of patients achieving a DLQI of 0 or 1 at Week 16
All secondary  anal yses will be based on FAS with NRI .
For the proportions, the risk difference will be computed and presented together with its 95% 
CI.
For the percentage improvement from baseline in PASI , analy sis of covariance (ANCOVA) 
will be used, comparing the mean percentage improvement from B aseline of PASI  between 
BI 695501 versus US -licensed Humira at Week 16. The estimate of the difference will be 
computed with its 95% CI .
ANCOVA will be perform ed based on the following model :
(M2)PASI  percentage improvement from baseline at Week 16 = treatment + Baseline PASI  
+ random error
The covariates will be handled in a similar way  to those described in model M1.
Secondary  Safet y Endpoints [IP_ADDRESS]
The secondary  endpoint is:
Proportion of patients with drug -related AEs .
 
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 61of 84
Proprietary confidential information © [ADDRESS_915840]-03(13.0)/Saved on: 05 Aug 2015 
 
 
 
 
 
 
 
 
 
 
 
7.3.4 Safety analyses
Adverse events will be coded using the Medical Dictionary  for Drug Regulatory  Activities 
(MedDRA). Theanalysis of AEs wi ll be based on the concept of treatment -emergent AEs.
That means that all AEs with an onset between start of treatment and end of the REP, a 
period of [ADDRESS_915841] dose of trial medication, will be assigned to the treatment 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 62of 84
Proprietary confidential information © [ADDRESS_915842]-03(13.0)/Saved on: [ADDRESS_915843] drug intake and deteriorate under treatment 
will also be considered as ‘treatment- emergent’. Other AEs will be assigned to the 
appropriate trial phases, i.e., screening or post -treatment.
All treated patients will be included in the safet y analysis. In general, safet y anal yses will be 
descriptive in nature and will be based on BI standards. No h ypothesis testing is planned.
Statistical analy sis and reporting of adverse events will concentrate on treatment -emergent 
adverse eve nts. To this end, all adverse events occurring between start of treatment and end 
of the residual effect period will be considered ‘treatment- emergent’. The resid ual effect 
period is defined as [ADDRESS_915844] drug intake and deteriorate under treatment will also be consider ed as 
‘treatment -emergent’.
Frequency , severit y, and causal relationship of adverse events will be tabulated b y system 
organ class and preferred term after coding according to the current version of the Medical 
Dictionary  for Drug Regulatory  Activities (MedDRA).
Laboratory  data will be analy sed both quantitatively  as well as qualitatively. The latter will 
be done via comparison of laboratory data to their reference ranges. Values outside the 
reference range as well as values defined as clinically  relevant will be highlighted in the 
listings. Treatment groups will be compared descriptively  with regard to distribution 
parameters as well as with regard to frequency  and percentage of patients with abnormal 
values or clinicall y relevant abnormal values.
Vital signs, ph ysical examinations, or other safet y-relevant data observed at screening, 
baseline, during the course of the trial and at the end -of-trial evaluation will be assessed with 
regard to possible changes compared to findings before start of treatment.
Safety  anal yses will be descriptive in nature. No formal inferential anal yses are planned for 
safet y comparison. The analyses will be on the SAF . Frequency  of adve rse events will be 
tabulated overall and by [CONTACT_676993] .In addition, risk ratio together with 95% CIs will be presented
for the overall proportion .
 
 
 
 
 
 
 
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 63of 84
Proprietary confidential information © [ADDRESS_915845]-03(13.0)/Saved on: 05 Aug 2015 
INTERIM ANALYSES 7.4
For this trial a “Fast track ” anal ysis is planned for anal ysesof the primary  efficacy  endpoint. 
After all prim ary efficacy  endpoint data are available and cleaned ( i.e. approximately  [ADDRESS_915846] patient has been randomized) a snapshot of the database will be taken .
This snapshot will be used for performing the Fast track analy sis. 
Only  cumulated results will be presented, i.e. patient level data will be excluded. Details 
regarding statistical analysis will be outlined in the TSAP. 
Only  a selected team
,not involved into the trial activities, will have access to the unbli nded 
snapshot data and need to sign a confidentiality  agreement. To ensure that the data integrit y 
of the continuing trial will not be violated, a charter will be prepared beforehand, outlining 
the procedures to be followed. This document will describe the measures to be implemented 
by [CONTACT_676994] y of the trial until the final database. Team members 
involved in the conduct of the trial as well as the site personnel and patients will remain 
blinded until the final database lock.
7.4.1 F inal analysis
A final analysis (including all endpoints ) will be performed when all trial data are available, 
i.e., approx. [ADDRESS_915847] track analysis will be repeated with the (partiall y) update d data, in 
particular with respect to safet y collected at Week [ADDRESS_915848] efficacy 
assessment ( Table [IP_ADDRESS]: 1) prior to the primary  endpoint assessment will be considered as a 
non-responder. This is referred to as ‘NRI’. 
For other endpoints, rules for handling of missing data will be specified in the TSAP, if 
necessary .
7.5.2 Safety and other endpoints
In case of missing AE relationship status, the AE will be considered as related. For other 
safet y endpoints, rules for handling of missing data will be specified in the TSAP, if 
necessary .

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 64of 84
Proprietary confidential information © [ADDRESS_915849]-03(13.0)/Saved on: 05 Aug 2015RANDOMIZ ATION 7.6
Patients who meet all the inclusion criteria and none of the exclusion criteria will be 
randomized 1:1 to either BI 695501 or Humira over the 24- week treatment period after the 
screening period . Randomization will be stratified according to prior exposure to a biologic 
agent (y es / no). Patie nts will be randomized sequentially  (the lowest sequentially  available 
randomization number)
Randomization can occur through a registration call or on Day  1 (-1 / +2) through a standard 
randomization visit call. The Day  1 randomization call will depend on the trial site procedure. 
Patients will be randomized to each treatment in a 1:1 ratio (BI 695501: US -sourced Humira) 
using an IRT system . The registration call might be made [ADDRESS_915850] 
administration of trial medication . Eligible patients will then be confirmed on to the 
randomization scheme on Day 1 (or when the drug is at site) and will receive their first 
administration of trial medicatio n, according to their randomization.
Randomization will be performed in a blinded fashion by
 [CONTACT_12067]. Boehringer Ingelheim Pharma 
GmbH & Co. KG, Clinical Trial Supply  Unit or a third party  appointed by  [CONTACT_676995] a v alidated randomization number generating s ystem. 
Access to the randomization code will be controlled and documented. All persons directl y 
involved in the conduct of the trial have no access to the treatment allocation prior to final 
database lock . The bloc k sizes of the randomization will be documented in the CTR.
DETERMINATION OF SAM PLE SIZE 7.[ADDRESS_915851] BI 695501 versus US-licensed Humira with ≥ 85% power, 
approximately  300 patients are needed for this comparison (FAS).
For the calcula tion of the sample size a meta -analy sis on Week 16 data of the REVEAL and 
CHAMPI [INVESTIGATOR_676974] (R14-4849, R14 -4898
)was performed. This meta -analysis revealed a risk 
difference of 64.2% and a 95% CI (60.4% to 67.9%). Table 7.7: 1 shows the information 
used in the meta -analysis.
The classical 95 -50-95 approach would give a non- conservative acceptance margin of 30.2% 
for the risk differe nce preserving 50% of the Humira effect. 
Calculation of a conservative equivalence margin
Preserve 70% of the lower confidence limit (lcl) 60.4% (obtained from the meta -analysis) of 
the historical effect over placebo. Equivalence margin = (1 –preserved proportion)*lcl, 
(1-0.7)*60.4% = 18%. 
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 65of 84
Proprietary confidential information © [ADDRESS_915852]-03(13.0)/Saved on: 05 Aug 2015Table 7.7: 1 CHAMPI [INVESTIGATOR_676975] s 
PlaceboTreatment Placebo
Events Total % Events Total %
CHAMPI [INVESTIGATOR_45372] 86 108 79.6% 10 53 18.9%
REVEAL 578 814 71% 26 398 7%
The weighted mean response rate is assumed to be the true response rate of 72% .
This sample size is based on an assumed treatment difference in proportions of patients with 
PASI  75 at Week 16 of 0%, a standard proportion of 72% and an equivalence margin of 18%.
At a power of 85% the sample size would be 288. 
Table 7.7: 2 present s the sample size at different m argins and different power.
Table 7.7: 2 Sample size according to different scenarios
Assu med true response rate 
(RR)Margin Confidence le vel 
(two -sided)Power Sample Size#
Equivalence
72% 15% 95% 75% 340
72% 15% 95% 80% 366
72% 15% 95% 85% 414
72% 15% 95% 90% 572
72% 18% 95% 75% 234
72% 18% 95% 80% 256
72% 18% 95% 85% 288
72% 18% 95% 90% 330
72% 20% 95% 75% 188
72% 20% 95% 80% 200
72% 20% 95% 85% 228
72% 20% 95% 90% 262
#Allocation ratio 1:1
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 66of 84
Proprietary confidential information © [ADDRESS_915853]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. INFORMED CONSENT, TRIAL RECORDS , DATA 
PROTECTION, PUBLICATION POLICY
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the I CH Harmonized Tripartite Guideline 
for GCP ,relevant BI SOPs ,the EU regulation 536/2014 )and other relevant regulations.
Standard medical care (prophy lactic, diagnostic and therapeutic procedures) remains the 
responsibility  of the treating phy sician of the patient.
The Investigator will inform the sponsor immediately  of any  urgent safet y measures taken to 
protect the trialsubjects against any  immediate hazard, as well as of any serious breaches of 
the protocol or of ICH GCP*.
The BI transparency  and publication policy  can be found on the following web page : 
trials.boehringer -ingelheim.com. 
The rights of the Investigator and of the sponsor with regard 
to publication of the results of this trial are described in the Investigator contract. 
The certificate of insurance cover is made available to the Investigator and the patients, and is
stored in th e ISF.
TRIAL APPROVAL, PATIENT IN FORMATION, INFORMED 8.1
CONSENT
This trial will be initiated only  after all required legal documentation has been reviewed and 
approved b y the respective IRB/ IECand CAaccording to national and international 
regulations. The same applies for the implementation of changes introduced by [CONTACT_15635].
Prior to patient participation in the trial, written informed consent must be obtained from each 
patient (or the patient’s legally accepted representative) according to ICH / GCP and to the 
regulatory  and legal requirements of the participating country . Each signature [CONTACT_15649] y dated b y each signatory  and the informed con sent and any  additional 
patient -information form retained b y the Investigator as part of the trial records. A signed 
copy  of the informed consent and any  additional patient information must be given to each 
patient or the patient’s legall y accepted representative.”
The Investigator must give a full explanation to trial patients based on thepatient information 
form . A language understandable to the patient should be chosen, t echnical terms and 
expressions avoided, if possible . The patient must be given sufficient time to consider 
participation in the trial. The Investigator obtains written consent of the patient’s own free 
will with the informed consent form after confirming that the patient understands the contents. 
The Investigator must sign (or place a seal on) and date the informed consent form. If a trial 
collaborator has given a supplementary  explanation, the trial collaborator also signs (or 
places a s eal on) and dates the informed consent.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 67of 84
Proprietary confidential information © [ADDRESS_915854]-03(13.0)/Saved on: 05 Aug 2015Re-consenting may become necessary  when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
The consent and re -consenting process should be properl y documente d in the source 
documentation.
DATA QUALITY ASSURANCE 8.2
A quality  assurance audit/inspection of this trial may  be conducted by  [CONTACT_456] ,sponsor ’s 
designees ,or by [CONTACT_1744] /IECor by  [CONTACT_10200]. The quality  assurance auditor will 
have access to all medical records, the Investigator ’s trial -related files and correspondence, 
and the informed consent docume ntation of this clinical trial.
RECORDS 8.3
Electronic Case Report Forms for individual patients will be provided by  [CONTACT_456] .See 
Section [IP_ADDRESS] for rules about emergency  code breaks. For drug accountability , refer to 
Section 4.1.8
.
8.3.1 Source documents
Source documents provide evidence for the existence of the patient and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator ’s sit e.
Data reported on the eCRF must be consistent with the source data, or the discrepancies must 
be explained. The investigator may need to request previous medical records or transfer 
records, depending on the trial; current medical records must also be av ailable.
For the eCRF, all data must be derived from source documents:
In accordance with regulatory  requirements the Investigator should prepare and maintain 
adequate and accurate source documents and trial records that include all observations and 
other data pertinent to the investigation on each trial subject. Source data as well as reported 
data should follow good documentation practices and be attributable, legible, 
contemporaneous, original and accurate. Changes to the data should be traceable (aud it trail).
Data reported on the e
CRF must be consistent with the source data or the discrepancies must 
be explained.
Before providing an y copy  of patients’ source documents to the sponsor ,the investigator 
must ensure tha t all patient identifiers (e .g. patient’s name, initials, address, phone number, 
social securit y number ) have properl y been removed or redacted to ensure patient 
confidentiality .
If the patient is not compliant with the protocol , any  corrective action ,e.g.,re-training must 
be documented in the patient file.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 68of 84
Proprietary confidential information © [ADDRESS_915855]-03(13.0)/Saved on: [ADDRESS_915856] safet y and data quality .
The Investigator /institution will allow on -site trial -related monitoring, audits, I RB/IEC 
review and regulatory  inspections. Direct access should be granted to all source documents 
(paper and e -records )including progress notes, copi[INVESTIGATOR_181955]. 
The Clinical Research Associate (CRA )and auditor may  review all CRFs and informed 
consents. The accuracy  of the data will be verified by  [CONTACT_676996] S ection 8.3.1. The sponsor will also monitor compliance with the 
protocol and ICH GCP.
8.3.3 Storage period of records
Trial site(s):
The trial site(s) must retain the source and essential documents (including ISF) according to 
the national or local requirements (whatever is longer) valid at the time of the end of the trial .
Sponsor :
The sponsor must retain the essential documents according to the sponsor ’s SOPs.
EXPEDITED REPORTING OF  ADVERSE EVENTS 8.[ADDRESS_915857] parties is prohibited with the exceptions noted below. Patient privacy will 
be ensured b y using patient identifica tion code numbers.
Data protection and data securit y measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 6 and 12 of the World Health 
Organization ( WHO ) GCP handbook.
Treatment data may  begiven to the patient’s personal phy sician or to other appropriate 
medical personnel responsible for the patient’s welfare. Data generated as a result of the trial 
need to be available for inspection on request b y the participating ph ysicians, the sponsor ’s 
representatives, b y the IRB / IEC and the regulatory authorities .
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 69of 84
Proprietary confidential information © [ADDRESS_915858]-03(13.0)/Saved on: [ADDRESS_915859] to comply  with the applicable rules for the collection, storage and 
future use of biological samples from clinical trial participants and the corresponding data, in 
particular
A Quality  Management Sy stem has been implemented to ensure the adherence with the 
Principles of GCP as outlined in 'Note For Guidance On Good Clinical Practice' 
(CPMP/I CH/13 5/95) .
The BI -internal facilities storing and anal yzing biological samples and data from clinical 
trial partic ipants as well as the laboratories’ activities for clinical trials sponsored by  [CONTACT_676997] y audited. The anal ytical groups and the banking facility are therefore assessed 
to be qualified for the storage and use of biological samples and data collected in clinical 
trials.
Samples and data are used only  if an appropriate informed consent is available.
TRIAL MILESTONES 8.[ADDRESS_915860] patient in the whole trial 
(“Last Patient Out” ).
The “ Last Patient Drug Discontinuation ”(LPDD) date is defined as the date on which the 
last patient at an individual trial site ends trial medication (as scheduled per protocol or 
prematurel y). Individual Investigator s will be notified of S[LOCATION_003]Rs occurring with the trial 
medication until [ADDRESS_915861].
The IEC/CAin each participating EU member state will be notified about the trial 
milestones according to the respective laws.
A final report of the clinical trial data will be written only  after all patients have completed 
the trial in all countries (EU or non -EU) to incorporate and consider all data in the report.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 70of 84
Proprietary confidential information © [ADDRESS_915862]-03(13.0)/Saved on: [ADDRESS_915863] patient (EU or 
non-EU).
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 71of 84
Proprietary confidential information © [ADDRESS_915864]-03(13.0)/Saved on: 05 Aug [ZIP_CODE]. REFERENCES
PUBLISHED REFERENCES 9.1
R05-2548 Finlay  AY, Khan GK. Dermatology  Life Quality  Index (DLQI) - a simple
practical measure for routine clinical use. Joint Ann Mtg of the British 
Association of Dermatologists and the Canadian Dermatology  Association, 
Oxford, 6 - 10 Jul 1993 Clin Exp Dermatol 1994. 19:210 -216.
R08-1089 Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therap y of psoriasis.
Nature 2007; 445(7130):866 -
873.
R11-1257 Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J 
Med 2009; 361(5):496 -509.
R11-1259 Menter A, Griffiths CEM. Psoriasis 2: current and future management of 
psoriasis. Lancet 2007; 370:272 -284.
R11-1501 Adalimumab (LU 200134), anti-tumor necrosis factor alpha (TNF-alpha IgG1 
monoclonal antibody ) (Abbott L aboratories): Clinical pharmacology  and 
biopharmaceutics review(s), application number:125057/0. 
Webpage: fda.gov/downl oads/Drugs/DevelopmentApprovalProcess/ 
HowDrugsareDevelopedandApproved/ApprovalApplications/ 
TherapeuticBiologicApplications/ucm092770.pdf (access date: 
27October 2011); Center for Drug Evaluation and Research, Center for 
Biologics Evaluation and Research (2002).
R11-[ADDRESS_915865] Dermatol 
2008. 128:1325-1327.
R13-[ADDRESS_915866] DE, Alten R, Bingham C, Yocum D, Sloan V, Tsuji W, 
Stevens R, Fries J, Witter J, Johnson K, L assere M, Brooks P. Standardizing 
assessment and reporting of adverse effects in rheumatology  clinical trials II: 
the Rheumatology  Common Toxic ity Criteria v.2.0. J Rheumatol 2007. 
34(6):1401-1414.
R14-3562 Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, 
Ortmeier B, Kricorian G. Validation of the Psoriasis Sy mptom Inventory  
(PSI), a patient- reported outcome measure to assess pso riasis symptom 
severit y. J Dermatol Treat 2013. 24(5):356-360.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 72of 84
Proprietary confidential information © [ADDRESS_915867]-03(13.0)/Saved on: 05 Aug 2015R14-3559 Revicki DA, Jin Y, Wilson HD, Chau D, Viswanathan HN. Reliability  and 
validity  of the psoriasis sy mptom invento ry in patients with 
moderate -to-severe psoriasis. J Dermatol Treat 2014. 25(1):8-14.
R14-4849 Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy  
and safet y of adalimumab in patients with moderate to severe psoriasis treated 
continuously  over 3 years: results from an open -label extension study  for 
patients f rom REVEAL. J Am Acad Dermatol 2012. 66(2):241-251.
R14-4898 Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink 
K, Kaul M, Camez A, CHAMPI[INVESTIGATOR_676976]. Efficacy  and safety  
results from the randomized controlled comparati ve study  of adalimumab vs. 
methotrexate vs. placebo in patients with psoriasis (CHAMPI[INVESTIGATOR_45372]). Br J 
Dermatol 2008. 158(3):558-566.
R14-5159 Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, 
Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mis try S, Bergmans P, 
Barker J, TRANSI T Investigators. One -year safety  and efficacy  of 
ustekinumab and results of dose adjustment after switching from inadequate 
methotrexate treatment: the TRANSIT randomized trial in moderate -to-severe 
plaque psoriasis. Br J Dermatol 2014. 170(2):435 -444.
R15-1219 Martin ML , McCarrier KP, Chiou CF, Gordon K, Kimball AB, Voorhees AS 
van, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G. 
Early development and qualitative evidence of content validity  for the 
Psoriasis Sy mptom Inventory  (PSI), a patient-reported outcome measure of 
psoriasis sy mptom severity . J Dermatol Treat 2013. 24(4):255-260.
R15-
1393 Davidovici BB, Sattar N, Joerg PC, Puig L , Emery  P, Barker JN, Kerkhof P 
van de, Stahle M, Nestle FO, Girolomo ni G, Krueger JG, Psoriasis Education 
and Learning S yllabus (PEARL S). Psoriasis and sy stemic inflammatory  
diseases: potential mechanistic links between skin disease and co -morbid 
conditions. J I nvest Dermatol 2010. 130(7):1785-1796.
R15-[ADDRESS_915868] Health Assessment Questionnaire: a review of 
its history , issues, progress, and documentation. J Rheumatol 2003. 
30(1):167-178.
R15-3849 The Health Assessment Questionnaire (HAQ) and the improved HAQ 
(formerl y called the PROMI S HAQ) (revi sed June 2009). 
Webpage: aramis.stanford.edu/downloads/HAQ%20I nstructions%20(ARAMI S
)%206 -30-09.pdf (access date: 15 July  2015) ; Stanford: Stanford University  
School of Medicine, Division of I mmunology  & Rheumatology  2009
 
 

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 73of 84
Proprietary confidential information © [ADDRESS_915869]-03(13.0)/Saved on: 05 Aug 2015 
R15-5978 Humira®(adalimumab) injection, for subcutaneous use ([COMPANY_013]) (U.S. 
prescribing information, revised: 11/2015 website 
rxabbvie.com/pdf/humira.pdf.
R16-[ADDRESS_915870] 2008 ; 118 (2):597 -607.
R16-0358
Humira 40 mg/0.8 ml solution for in jection for paediatric use, Humira 
40 mg/0.8 ml solution for injection in pre-filled syringe, Humira 40 mg/0.[ADDRESS_915871], Humira 
40mg/0.8 ml solution for injection in pre -filled pen, Humira 40 mg/0.4 ml 
solution for injection in pre-filled s yringe, Humira 40 mg/0.4 ml solution for 
injection in pre- filled pen ([COMPANY_013]) (summary  of product characteristics, 
manufacturer(s) of the biological active substance(s) and manufacturers 
responsible for batch releas e, conditions or restrictions regarding suppl y and 
use, other conditions and requirements of the marketing authorisation, 
conditions or restrictions with regard to the safe and effective use of the 
medicinal product, labelling and package leaflet, last upd ated: 28/01/2016).
webpage: ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Product_I nformation/ human/000481/WC500050870.pdf (access date: 29 
January  2016) (2016)
R96-3541 Fredriksson T, Pettersson U. Severe psoriasis -oral therap y with a new 
retinoid. Dermatologica 1978; 157:238 -244.
UNPUBLISHED REFERENC ES 9.2
U13-1096-01 . Pharmacokinetics 
and safet y of BI 695501 in healthy subjects: a randomized, open -label, 
single -dose, parallel arm, active -comparator clinical Pha se I stud y. 1297.1 , 24 
Jan 2013.
c01843589 ib-bi-[PHONE_13598]-p1
c02158186 Efficacy , safety  and immunogenicity  of BI 695501 versus adalimumab in 
patients with active rheumatoid arthritis: a randomized, double -blind, parallel 
arm, multiple dose, active comparator trial . 1297.2, 16 Aug 2013.
c03070713 . Pharmacokinetics 
and safet y of BI 695501 in healthy subjects: a rando mized, open -label, 
single -dose, parallel arm, active -comparator clinical Pha se I stud y. 1297.1 , 24 
Jan 2013.

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 74of 84
Proprietary confidential information © [ADDRESS_915872]-03(13.0)/Saved on: 05 Aug 201510. APPENDICES
CLINICAL EVALUATION OF LIVER INJURY 10.1
10.1.1 Introduction
Alterations of liver laboratory  parameters, as described in Section 5.3.6 (Protocol -specified 
AESI s), are to be further evaluated using the following procedures.
10.1.2 Procedures
Repeat the following laboratory tests: ALT, AST, and bilirubin (total and direct) -within 48 
to 72 hours. If it is confirmed that ALT and/or AST values ≥ [ADDRESS_915873] occur in 
conjunction with an elevation of total bilirubin of ≥2 times UL N, the laboratory  parameters 
listed below (clinical chemistry , serology , hormones, haematology ) must be determined and 
made available to the investigator and to BI as soon as possible.
In addition,
obtain a detailed history  of current sy mptoms and concurrent diagnoses and medical 
history  according to the ‘DILI checklist’ provided in the I SF
obtain history  of concomitant drug use (including non- prescription medications, 
herba l and dietary  supplement preparations), alcohol use, recreational drug use, and 
special diets according to the ‘DILI checklist’ provided in the I SF;
obtain a history  of exposure to environmental chemical agents (consider home and 
work place exposure) according to the ‘DILI checklist’ provided in the I SF;
and report these via the CRF.
Clinical chemistry
Alkaline phosphatase, albumin, PT or I NR, CK, CK -MB, coeruloplasmin, α
-1 antitry psin, 
transferin, amy lase, lipase, fasting glucose, cholesterol, trigl ycerides
Serology
Hepatitis A (Anti- IgM, Anti -IgG), Hepatitis B (HbsAg, Anti- HBs, DNA), Hepatitis C 
(Anti -HCV, RNA if Anti -HCV positive), Hepatitis D (Anti -IgM, Anti -IgG), Hepatitis E 
(Anti -HEV, Anti -HEV IgM, RNA if Anti- HEV IgM positive), Anti -Smooth Muscle antibody  
(titer), Anti -nuclear antibody  (titer), Anti -LKM (liver -kidney  microsomes) antibody , 
Anti- mitochondrial antibody
Hormones, tumor marker
TSH
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 75of 84
Proprietary confidential information © [ADDRESS_915874]-03(13.0)/Saved on: 05 Aug 2015Hematology
Thrombocy tes, eosinophils
Provide abdominal ultrasound to rule out biliary  tract, pancreatic or intrahepatic 
pathology , e.g. bile duct stones or neoplasm.
Initiate close observation of subjects b y repeat testing of ALT, AST, and total 
bilirubin (total and direct) at least weekl y until the laboratory ALT and/or AST 
abnormalities stabilize or return to normal, then monitor further as specified in the 
CTP. Depending on further laboratory  changes, additional parameters identified, e.g.,
by [CONTACT_676998].
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 76of 84
Proprietary confidential information © [ADDRESS_915875]-03(13.0)/Saved on: [ADDRESS_915876] all or all lesions
Figure 10.2: 1 sPGA Rating Scale for Overall Psoriatic Disease
Figure 10.2: 2 Body Surface Area Involved in Psoriasis

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 77of 84
Proprietary confidential information © [ADDRESS_915877]-03(13.0)/Saved on: 05 Aug 2015Figure 10.2: 3 Dermatology  Life Quality  Index

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 78of 84
Proprietary confidential information © [ADDRESS_915878]-03(13.0)/Saved on: 05 Aug 2015Figure 10.2: 4 PASI

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 79of 84
Proprietary confidential information © [ADDRESS_915879]-03(13.0)/Saved on: 05 Aug 2015

Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 80of 84
Proprietary confidential information © [ADDRESS_915880]-03(13.0)/Saved on: [ADDRESS_915881] PARTY 10.3
BLINDING
This is a double -blind trial , therefore patients, investigators, and trial personnel (except the 
trial personnel administering the trial medication at site) will remain blinded with regard to 
the randomized treatment assignments until after database lock. 
To prevent unblinding, a designated, person will receive the trial medication at site. I n 
addition, a qualified unblinded designee will administer the trial medication, maintain records 
of the produc t’s delivery  to the trial site, the inventory  at the site, as well as will be 
responsible for preparation of unused trial medication for return to the sponsor or destruction 
in a blinded fashion and in accordance with local requirements .
Records of the pr oduct’s delivery  to the trial site will include dates, quantities, batch/serial 
numbers, expi[INVESTIGATOR_4061]  (‘use by’) dates and the unique code numbers assigned to the investigational 
products and trial patients. The designated unblinded person will maintain records that 
document doses administration to patients and reconcile all investigational product received 
at site. These records should be kept separate from the patients file and not be accessible for 
the blinded personal. At the time of return to the sponsor or local destruction, the designated 
unblinded person must verify  that no supplies remained at the trial site. 
The unblinded trial personnel administering the trial medication will not be involved in any  
other trial assessments or procedures.
A description of the trial medication is provided in Table 4.1.1: 1.
Patient blinding procedure
Trial medication will be administered by  [CONTACT_676999] -administration 
will be allowed . To ensure patient’s blinding during the administration process, the following 
procedures are to be applied:
Syringes unpacked and prepared for injection are to be covered by  a surgical drape at the 
time of patient preparation for dosing. The same procedure is to be applied to used 
syringes after injection.
During the dose administration, patients are to be separated from the unblinded designee 
who will administer the trial medication, b y surgical drape, screen or pi[INVESTIGATOR_6356].
If a patient’s dosing is required in a supi[INVESTIGATOR_2547], the screen or c urtain (the way  it is 
used during surgery ) or towel are to be put at chest level.
Site staff blinding procedure
Responsibilities for blinded and unblinded study  site staff are defined below. At each site, a 
form with the name(s) of the staff members, blinded and unblinded, with their respective 
responsibilities will be filled in.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 81of 84
Proprietary confidential information © [ADDRESS_915882]-03(13.0)/Saved on: 05 Aug 2015(NOTE: all personnel noted below will have signed the Site Personnel Signature [CONTACT_94618], clearl y 
outlining each individual’s responsibility ). 
In case of non- availability  of blin ded or unblinded study  staff, the Clinical Research 
Organization and sponsor should be informed immediately . 
Blinded Personnel Main Responsibilities
Principal Investigator:
[INVESTIGATOR_605269]Remains blinded to the medication assignment 
during the whole trial
Monitors patient status
Responsible for the delegation of tasks to 
appropriate staff and to ensure correctness of all 
assessments
Provides direct patient care
Works and communicates with blinded CRA
Ensures adequate unblinded pharmacy staff and 
medication administrator and facilities
Contacts IXRS®to enter screen failures, screened 
patients, randomizations and obtain subsequent 
medication assignments 
Independent Joint Assessor:
CANNOT ADMINISTER THE MEDICATIONRemains blinded to the medication assignment 
during the whole trial
Joint assessment
Blinded Sub -Investigator or Study Coordinator/Study 
Nurse:
CANNOT ADMINISTER THE MEDICATIONRemains blinded to the medication assignment 
during the whole trial
Contacts IXRS to enter screen failures, screened 
patients, randomizations and obtain subsequent 
medication assignments 
Monitors patient status
Provides direct patient care if applicable
Works and communicates with blinded monitor
Blinded CRA :
CANNOT MAKE SAFETY OR EFFICACY 
EVALUATIONS
CANNOT ADMINISTER THE MEDICATION Remains blinded to the medication assignment 
during the whole trial
Acts as the primary point of contact [CONTACT_677000]
Provides ongoing site support in all areas of trial 
conduct, except a ccountability and reconciliation 
of trial medication
Conducts blinded site monitoring visits and 
performs source document verification
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 82of 84
Proprietary confidential information © [ADDRESS_915883]-03(13.0)/Saved on: [ADDRESS_915884]/Back -up Unblinded 
Pharm acist: 
CANNOT MAKE SAFETY OR EFFICACY 
EVALUATIONSReceives trial medication; unpacks, inventories 
and stores trial medication in a secure, limited 
access refrigerator
Revie ws ELPRO Libero temperature monitoring 
device for shipment temperature excursions
Acknowledges trial medication receipt in IXRS
Registers the trial medication in IXRS
Com pletes the Master Drug Accountability Log 
and Subject Drug Dispensing Log
Monitors temperature using min/max. 
thermometer and completes refrigerator 
temperature storage log
Reports temperat ure excursions to unblinded 
monitor
Receives the kit numbers for injection from IXRS 
confirmation
Dispenses trial medication to the unblinded 
medication administrator
Trains back -up pharmacist(s), if applicable
Implem ents blinding plan
Monitors and maintai ns drug inventory at site
Reports all protocol deviations regarding dosing 
errors to the unblinded CRA
Ensures all accountability logs are kept separate 
from the medication blinded staff
Works and communicates with unblinded monitor
Retain sused kits for reconciliation by [CONTACT_656840]. Destroys used 
medication per SOPs.
Set Unblinded Trial Medication Administrator:
(Sub -Investigator or study nurse)
Back -up Unblinded Trial Medication Administrator: 
CANNOT MAKE SAFETY OR EFFICACY 
EVALUATIONSCooperates w ith the unblinded pharmacist 
Performs the trial medication administration and 
ensures patient is blinded during IP administration
Works and communicates with unblinded CRA
Unblinded CRA :
CANNOT MAKE SAFETY OR EFFICACY 
EVALUATIONS
CANNOT ADMINISTER THE MEDICATIONActs as the primary point of contact [CONTACT_656841]
Provides ongoing site support in the management 
of trial medication
Conducts unblinded site monitoring visits and 
monitors accountability of trial medication
CRA = clinical research associate
Training
All professional personnel taking part in the clinical trial are trained and aware of the need to 
respect study blinding principles as foreseen b y the protocol. Blinded and unblinded study  
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 83of 84
Proprietary confidential information © [ADDRESS_915885]-03(13.0)/Saved on: 05 Aug 2015site staff as well as blinded and unblinded CRAs will be trained on study  blinding procedures 
before the start of an y study  activities at site. Unblinded study  site staff is restricted to 
persons handling trialmedications including the injection of study  drug. Training in study  
blinding procedures for blinded and unblind ed study  CRAs will be provided during a CRA 
Meeting. Training in study blinding procedures for blinded and unblinded site staff will be 
provided at the Investigators’ Meeting; during workshop sessions, separately designed for 
blinded and unblinded study  personnel in which CRAs will participate, as well. Part of both 
workshops will review the Medication Blinding Procedures, with blinding procedures 
described. For the rest of site staff, who did not participate in an Investigators’ Meeting, 
applicable trainin g in study  blinding procedures will be provided by  a blinded CRA during 
the Site I nitiation Visit, based on information in Study  Protocol, Medication Blinding 
Procedures and Pharmacy  Manual. Such training is a part of study  specific agenda for Site 
Initiat ion Visit, as well as slide presentation prepared for the visit. A ll training will be 
documented.
Boehringer Ingelheim 26Apr 2016
BI Trial No.: 1297.12
c08917790-03 Trial Protocol Page 84of 84
Proprietary confidential information © [ADDRESS_915886]-03(13.0)/Saved on: 05 Aug 201511. DESCRIPTION OF GLOBA L AMENDMENT(S)
“This is the original protocol.”
Number of global amendment
Date of CTP revision
EudraCT number
BI Trial number
BI Investigational Product(s)
Title of protocol
To be implemented only after 
approval of the IRB /IEC /
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB /IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed
Description of change
Rationale for change
   
 
APPROVAL / SIGNATURE [CONTACT_15650]:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
[CONTACT_1641]:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
 
   
   
 
   
   
 
   
   
 
   
   
 
  
  
   
 
   
   
 
  
  
   
 
  
  
 c08917790 3.0
clinical-trial-protocol
Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira in Patients with
Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind,Parallel-Arm, Multiple-Dose, Active Comparator Trial
Author-Clinical Monitor 26 Apr 2016 13:[ADDRESS_915887]
Author-Clinical Program 26 Apr 2016 13:[ADDRESS_915888]
Approval-Therapeutic Area 26 Apr 2016 14:[ADDRESS_915889] 27 Apr 2016 14:[ADDRESS_915890]
Author-Trial Statistician 28 Apr 2016 07:[ADDRESS_915891]
Verification-Paper Signature
[CONTACT_15651]02 May 2016 11:[ADDRESS_915892]

Boehringer Ingelheim Page  2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c08917790 3.0